%PDF-1.3
%
1 0 obj
<<
/PageLabels 2 0 R
/Type /Catalog
/Pages 3 0 R
/Metadata 4 0 R
>>
endobj
5 0 obj
<<
/XPressPrivate <2525446F63756D656E7450726F63657373436F6C6F72733A20426C61636B0A2525456E64436F6D6D656E7473>
/Producer (QuarkXPress\(tm\) 6.5)
/CreationDate (20070509233315)
/Creator (QuarkXPress\(tm\) 6.5)
/ModDate (D:20220412194442+00'00')
>>
endobj
2 0 obj
<<
/Nums [0 6 0 R]
>>
endobj
3 0 obj
<<
/Type /Pages
/Kids [7 0 R 8 0 R 9 0 R 10 0 R 11 0 R 12 0 R]
/Count 6
>>
endobj
4 0 obj
<<
/Type /Metadata
/Subtype /XML
/Length 934
>>
stream
Not for further distribution unless allowed by the License or with the express written permission of Cambridge University Press.
https://doi.org/10.1017/S0317167100005631
https://doi.org/10.1017/S0317167100005631 Published online by Cambridge University Press
2022-04-12T19:44:42+00:00
endstream
endobj
6 0 obj
<<
/St 84
/S /D
>>
endobj
7 0 obj
<<
/Parent 3 0 R
/Contents [13 0 R 14 0 R 15 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F1 16 0 R
/F2 17 0 R
/F0 18 0 R
/F4 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [23 0 R]
>>
endobj
8 0 obj
<<
/Parent 3 0 R
/Contents [24 0 R 25 0 R 26 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/XObject <<
/Fm0 27 0 R
>>
/ProcSet [/PDF /Text]
/Font <<
/F9 28 0 R
/F1 16 0 R
/F2 17 0 R
/F8 29 0 R
/F0 18 0 R
/F6 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [30 0 R]
>>
endobj
9 0 obj
<<
/Parent 3 0 R
/Contents [31 0 R 32 0 R 33 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F1 16 0 R
/F10 34 0 R
/F8 29 0 R
/F0 18 0 R
/F5 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [35 0 R]
>>
endobj
10 0 obj
<<
/Parent 3 0 R
/Contents [36 0 R 37 0 R 38 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F1 16 0 R
/F2 17 0 R
/F8 29 0 R
/F0 18 0 R
/F5 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [39 0 R]
>>
endobj
11 0 obj
<<
/Parent 3 0 R
/Contents [40 0 R 41 0 R 42 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F1 16 0 R
/F0 18 0 R
/F3 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [43 0 R]
>>
endobj
12 0 obj
<<
/Parent 3 0 R
/Contents [44 0 R 45 0 R 46 0 R]
/MediaBox [0 0 594 783]
/Resources <<
/ProcSet [/PDF /Text]
/Font <<
/F2 17 0 R
/F0 18 0 R
/F3 19 0 R
>>
/ExtGState <<
/GS2 20 0 R
/GS1 21 0 R
/GS0 22 0 R
>>
>>
/Type /Page
/Annots [47 0 R]
>>
endobj
13 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
14 0 obj
<<
/Length 9238
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 29.4312 Tm
0 0 0 1 k
(S84)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.3994 182.0051 Tm
0 0 0 1 k
0.066 Tw
(There are approximately 350,000 Canadians estimated to be)Tj
-1.26316 -1.15789 TD
0.016 Tc
0.359 Tw
[(suf)18(fering from dementia today)65(, the majority (65%) from)]TJ
T*
0 Tc
0 Tw
(Alzheimer)Tj
4.25659 0.00001 TD
Tj
0.27783 0.00001 TD
-0.0001 Tc
(s)Tj
0.8209 0 Td
0 Tc
0.182 Tw
(disease (AD). )Tj
6.09305 0.00001 TD
(The incidence rate of dementia in)Tj
-11.44837 -1.15792 TD
0.175 Tw
(Canada is estimated at 20.6 new cases per 1,000 per annum.)Tj
0 -1.15789 TD
0.054 Tw
[(W)40(ith the projected growth of the senior population, the number)]TJ
T*
0.046 Tw
[(of af)18(fected individuals is predicted to increase to over a million)]TJ
0 -1.1579 TD
0.044 Tw
(in the next three decades.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 138.3468 119.14 Tm
0 0 0 1 k
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 144.1067 116.0051 Tm
0 0 0 1 k
0.044 Tw
(The associated costs of dementia are)Tj
-10.91656 -1.15789 TD
0.02 Tc
0.364 Tw
(incalculable for the patients and their families, and are)Tj
T*
0 Tc
0.012 Tw
(anticipated to be staggering for Canada\325)Tj
16.02686 0.00001 TD
-0.0001 Tc
(s)Tj
0.65116 0 Td
0 Tc
(health system. In 1991)Tj
-16.67803 -1.15791 TD
-0.0001 Tc
(a)Tj
0.75335 0 Td
0 Tc
0.06 Tw
(conservative health-economic study from the Canadian Study)Tj
-0.75335 -1.15789 TD
0.061 Tw
[(of Health and )55(Aging (CSHA) estimated the cost of care at $3.9)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 159.5244 620.5035 Tm
0 0 0 1 k
0.001 Tc
[(ABSTRACT)75(:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 216.4442 620.5035 Tm
0 0 0 1 k
0.038 Tw
[(Prevention in )55(Alzheimer)-3755(s disease and other dementias (AD/dementia) is defined on the)]TJ
-5.99156 -1.1579 TD
0.267 Tw
(basis of clinical states and their expressed symptoms. Primary prevention refers to delaying the)Tj
0 -1.15789 TD
0.209 Tw
(development of the full-blown state of clinically expressed disease in normal individuals. Current)Tj
T*
0.002 Tw
[(primary prevention research is driven by evidence of )55(AD/dementia protective factors that have emer)18(ged)]TJ
0 -1.1579 TD
0.107 Tw
[(from epidemiological studies. )18(The first randomized controlled trials \(RCT)69(s\) of primary )55(AD/dementia)]TJ
0 -1.15789 TD
0.362 Tw
[(prevention have been designed to test the ef)18(ficacy and safety of NSAIDs, hormonal therapy)65(,)]TJ
T*
0.026 Tw
[(antihypertensive drugs and antioxidants. )18(The experience of these trials has indicated safety concerns as)]TJ
0 -1.1579 TD
-0.0001 Tc
(a)Tj
0.84168 0 Td
0 Tc
0.148 Tw
[(key issue and highlighted significant design challenges in this type of research. )18(These trials have)]TJ
-0.84168 -1.15789 TD
0.007 Tw
(required lar)Tj
4.62469 0.00001 TD
[(ge sample sizes and unsustainable costs. )18(There should be consideration given in future trials)]TJ
-4.62469 -1.15789 TD
0.084 Tw
[(to enriching study samples with risk factors to increase progression rates to )55(AD/dementia. Innovative)]TJ
0 -1.1579 TD
0.098 Tw
(strategies will also be needed to recruit and retain subjects given the long follow-up periods, modest)Tj
0 -1.15789 TD
0.046 Tw
(perceived benefit and the potential for the risk-benefit ratio to change during the trial. It is foreseeable)Tj
T*
0.059 Tw
(that regulatory authorities will be presented with primary prevention RCT)Tj
30.03588 0 TD
-0.0001 Tc
(s)Tj
0.69802 0 Td
0 Tc
(for approval and labelling,)Tj
-30.7339 -1.1579 TD
0.025 Tw
(and that criteria to evaluate such evidence still need to be developed.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
8.5 0 0 8.5 159.5244 442.5035 Tm
0 0 0 1 k
0.001 Tc
-0.004 Tw
[(R\203SUM\203: )1(Pr\216venir)-228(et r)19(etarder)-227(l\325apparition de la MA/d\216mence. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 392.7154 442.5035 Tm
0 0 0 1 k
-0.004 Tw
(La pr\216vention de la maladie d\325Alzheimer (MA))Tj
-27.43423 -1.29412 TD
-0.026 Tw
(et des autres d\216mences (MA/d\216mence) se d\216finit sur des bases cliniques et symptomatiques. En pr\216vention primaire,)Tj
T*
0.182 Tw
(on cherche \210 retarder l\325apparition de la maladie av\216r\216e au point de vue clinique chez des individus normaux.)Tj
T*
0.05 Tw
(Actuellement, la recherche en pr\216vention primaire est bas\216e sur des donn\216es provenant d\325\216tudes \216pid\216miologiques)Tj
T*
0.254 Tw
(sur les facteurs de protection contre la MA/d\216mence. Les premiers essais contr\231l\216s randomis\216s (ECRs) en)Tj
T*
0.267 Tw
(pr\216vention primaire sur la MA/d\216mence ont \216t\216 con\215us pour \216valuer l\325ef)Tj
31.57799 0 TD
(ficacit\216 et la s\216curit\216 d\325AINSs, de)Tj
-31.57799 -1.29412 TD
0.2 Tw
[(traitements hormonaux, d\325antihypertenseurs et d\325antioxydants. L)92(\325exp\216rience acquise au cours de ces \216tudes a)]TJ
0 -1.29411 TD
0.042 Tw
(soulev\216 des questions importantes concernant la s\216curit\216 et a fait ressortir des d\216fis importants quant au plan de ce)Tj
0 -1.29412 TD
0.021 Tw
[(type de recherche. Ces essais n\216cessitent de tr\217s grands \216chantillons et entra\224nent des co\236ts prohibitifs. \313 l\325avenir)40(,)]TJ
-0.0001 Tc
(on)'
1.23321 0 Td
0 Tc
-0.017 Tw
(devrait consid\216rer enrichir les groupes en incluant des sujets ayant des facteurs de risque afin d\325augmenter le taux)Tj
-1.23321 -1.29412 TD
0.014 Tw
(de progression \210 la MA/d\216mence. Des strat\216gies novatrices seront \216galement n\216cessaires pour recruter et maintenir)Tj
T*
0.034 Tw
(la participation des sujets aux \216tudes \216tant donn\216 le suivi \210 long terme, les b\216n\216fices per\215us comme \216tant modestes)Tj
T*
-0.036 Tw
(et le taux de risques/b\216n\216fices qui peut changer pendant l\325\216tude. Il est \210 pr\216voir que des ECRs en pr\216vention primaire)Tj
T*
0.019 Tw
(seront pr\216sent\216s aux or)Tj
9.22822 0 TD
(ganismes de r\216gulation pour approbation et \216tiquetage du conditionnement des m\216dicaments)Tj
-9.22822 -1.29412 TD
0.025 Tw
(et que des crit\217res d\325\216valuation des donn\216es ainsi g\216n\216r\216es devront \220tre d\216velopp\216s.)Tj
ET
1 w
0 0 0 1 K
39.524 222.004 m
553.948 222.004 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 369.747 240.5034 Tm
0 0 0 1 k
0.025 Tw
(Can. J. Neurol. Sci. 2007; 34: Suppl. 1 - S84-89)Tj
ET
4 w
0 0 0 1 K
159.431 749.494 m
554.806 749.494 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
22 0 0 22 159.4306 719.4942 Tm
0 0 0 1 k
0.001 Tc
0.025 Tw
[(Primar)1(y Pr)19(evention and Delay of Onset)]TJ
0 -1.18182 TD
-0.031 Tw
(of AD/Dementia )Tj
ET
1 w
0 0 0 1 K
39.431 644.994 m
554.806 644.994 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
12 0 0 12 159.4306 663.4942 Tm
0 0 0 1 k
0.025 Tw
[(Howar)37(d H. Feldman, Claudia Jacova )]TJ
ET
0 0 0 0 k
307.8 69.757 247.176 74.736 re
f
1 w
0 0 0 1 K
307.8 121.775 m
554.976 121.775 l
S
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 307.8 103.2748 Tm
0 0 0 1 k
0.025 Tw
[(From the Division of Neurology)65(, Department of Medicine, University of British)]TJ
0 -1.14286 TD
[(Columbia, )18(V)111(ancouver)39(, B.C., Canada.)]TJ
1.71429 -1.14285 TD
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 324.4689 87.2747 Tm
0 0 0 1 k
(ECEIVED)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 348.8436 87.2747 Tm
0 0 0 1 k
(O)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 353.8971 87.2747 Tm
0 0 0 1 k
(CT)Tj
1.26 0.00001 TD
(OBER)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 376.4376 87.2747 Tm
0 0 0 1 k
0.025 Tw
(31, 2005. )Tj
3.99508 0.00001 TD
(A)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 409.4566 87.2747 Tm
0 0 0 1 k
(CCEPTED)Tj
4.81099 0.00001 TD
(IN)Tj
1.42138 0.00001 TD
(FINAL)Tj
3.27316 0.00001 TD
(FORM)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 475.8743 87.2747 Tm
0 0 0 1 k
(A)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
5.25 0 0 5.25 480.9278 87.2747 Tm
0 0 0 1 k
(PRIL)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 494.0334 87.2747 Tm
0 0 0 1 k
0.025 Tw
(2, 2006.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
7 0 0 7 307.8 79.2748 Tm
0 0 0 1 k
0.025 Tw
(Reprint r)Tj
3.62632 0.00001 TD
(equests to:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
7 0 0 7 365.412 79.2748 Tm
0 0 0 1 k
0.025 Tw
(Howard H. Feldman, Division of Neurology)Tj
17.80519 0.00001 TD
-0.0001 Tc
(,)Tj
0.52487 0 Td
0 Tc
(UBC Hospital, )Tj
-26.56035 -1.14287 TD
(S)Tj
0.83092 0 Td
[(192-221)37(1 )18(W)80(esbrook Mall, )17(V)111(ancouver)40(, B.C., )18(V6T)-258(2B5, Canada)1(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9 0 0 9 39.4306 741.3389 Tm
0 0 0 1 k
0.0013 Tc
(O)Tj
0.77732 0.00001 TD
0.001 Tc
[(RIGINAL)-164(A)-1(R)36(TICLE)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 309.5354 181.1132 Tm
0 0 0 1 k
-0.036 Tw
[(billion per year)40(, with anticipated escalating forward costs.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 527.0015 184.2483 Tm
0 0 0 1 k
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 531.9987 181.1132 Tm
0 0 0 1 k
[(T)70(aken)]TJ
-23.41719 -1.15789 TD
0.274 Tw
[(together)40(, these data provide a pressing tar)17(get for aging and)]TJ
T*
0.142 Tw
(dementia research directed at enabling individuals to maintain)Tj
ET
0.5 w
0 0 0 1 K
159.3038 751.2395 m
39.3998 751.2395 l
S
/GS2 gs
Q
endstream
endobj
15 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|]̗ǯḯr8 UaJ+sA1>Dcw#O*T V8Ux]t62;njn9=q5ُ.)VHcU$dO%EO
2ҴӤϘnĎcPv"WצUK7s
endstream
endobj
16 0 obj
<<
/LastChar 213
/FirstChar 32
/FontDescriptor 48 0 R
/Widths [250 0 0 0 0 0 0 0 332 332
0 0 0 332 250 277 0 0 0 0
0 0 0 0 0 0 332 0 0 0
0 0 0 721 666 721 721 666 610 776
776 388 0 0 666 942 721 776 610 0
721 555 666 721 721 998 0 721 0 0
0 0 0 0 0 499 555 443 555 443
332 499 0 277 0 0 277 831 555 499
555 0 443 388 332 0 499 0 0 499
0 0 0 0 0 0 0 0 0 666
0 0 0 0 0 0 0 0 0 0
443 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 332]
/Encoding 49 0 R
/Subtype /Type1
/BaseFont /LLIVZZ+Times-Bold
/Name /F1
/Type /Font
>>
endobj
17 0 obj
<<
/LastChar 208
/FirstChar 32
/FontDescriptor 50 0 R
/Widths [250 0 0 0 0 0 0 0 0 0
0 0 250 0 250 278 500 500 500 500
500 0 0 500 0 0 333 0 0 0
0 0 0 611 0 667 722 0 611 0
722 0 444 0 0 833 667 0 611 0
611 500 0 0 611 0 0 0 0 0
0 0 0 0 0 500 0 444 500 444
0 500 500 278 0 0 278 722 500 500
500 500 389 389 278 500 444 667 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 500]
/Encoding 51 0 R
/Subtype /Type1
/BaseFont /XRAHFI+Times-Italic
/Name /F2
/Type /Font
>>
endobj
18 0 obj
<<
/LastChar 213
/FirstChar 32
/FontDescriptor 52 0 R
/Widths [250 0 0 0 500 833 0 180 333 333
0 0 250 333 250 278 500 500 500 500
500 500 500 500 500 500 278 278 0 564
0 0 0 722 667 667 722 611 556 722
722 333 389 722 611 889 722 722 556 722
667 556 611 722 722 944 722 722 611 0
0 0 0 0 0 444 500 444 500 444
333 500 500 278 278 500 278 778 500 500
500 500 333 389 278 500 500 722 500 500
444 0 0 0 0 0 0 0 0 0
0 0 0 0 444 0 0 0 0 444
444 444 444 0 0 0 278 0 0 0
0 500 0 0 0 0 500 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 722 0 0 0 0 0 1000 444 444
333 333]
/Encoding 53 0 R
/Subtype /Type1
/BaseFont /CICWSW+Times-Roman
/Name /F0
/Type /Font
>>
endobj
19 0 obj
<<
/Type /Font
/BaseFont /AAALBE+NotoSans
/Subtype /Type0
/Encoding /Identity-H
/DescendantFonts [54 0 R]
/ToUnicode 55 0 R
>>
endobj
20 0 obj
<<
/OP false
/Type /ExtGState
>>
endobj
21 0 obj
<<
/OP true
/Type /ExtGState
>>
endobj
22 0 obj
<<
/OPM 1
/Type /ExtGState
>>
endobj
23 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 56 0 R
>>
endobj
24 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
25 0 obj
<<
/Length 14515
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 717.0228 Tm
0 0 0 1 k
0.292 Tw
(their cognitive capacity into old age, delaying the onset of)Tj
0 -1.15789 TD
0.259 Tw
[(impairment, and reducing the number of people af)18(fected by)]TJ
T*
0.074 Tw
(dementia. In this context, research strategies are now aiming at)Tj
0 -1.1579 TD
0.064 Tw
[(the prevention of )55(AD and other dementias (AD/dementia). )18(This)]TJ
0 -1.15789 TD
0.191 Tw
(paper proposes a framework for studies on the prevention of)Tj
T*
0.138 Tw
(AD/dementia, examines candidate interventions for prevention)Tj
0 -1.1579 TD
0.154 Tw
(and addresses the challenges that research will face in testing)Tj
0 -1.15789 TD
0.025 Tw
[(their ef)18(ficacy)64(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 618.0228 Tm
0 0 0 1 k
(W)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 49.524 618.0228 Tm
0 0 0 1 k
0.0028 Tc
(H)Tj
0.77876 -0.00001 TD
-0.074 Tc
[(AT)-424(I)-76(S)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 76.2649 618.0228 Tm
0 0 0 1 k
(M)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 85.2315 618.0228 Tm
0 0 0 1 k
0.0013 Tc
(E)Tj
0.66727 -0.00001 TD
0.001 Tc
[(ANT)-348(B)-1(Y)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 119.755 618.0228 Tm
0 0 0 1 k
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 125.5579 618.0228 Tm
0 0 0 1 k
0.0012 Tc
(R)Tj
0.72218 -0.00001 TD
0.001 Tc
[(EVENTION)-365(O)-2(F)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 183.1681 618.0228 Tm
0 0 0 1 k
0.001 Tc
(AD/D)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 206.3823 618.0228 Tm
0 0 0 1 k
0.0013 Tc
(E)Tj
0.66726 -0.00001 TD
0.001 Tc
(MENTIA)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 603.0228 Tm
0 0 0 1 k
0.215 Tw
[(Primary prevention in )55(AD/dementia refers to delaying the)]TJ
-1.26316 -1.15789 TD
0.333 Tw
(development of the full-blown state of clinically expressed)Tj
T*
0.011 Tw
(disease in normal individuals, while secondary prevention refers)Tj
0 -1.1579 TD
0.016 Tw
(to delaying the progression from earliest symptom expression to)Tj
0 -1.15789 TD
0.011 Tc
0.364 Tw
[(an overt disease state. )18(T)70(ertiary prevention coincides with)]TJ
T*
0 Tc
0.204 Tw
[(treatment, aiming to slow)65(, stop or reverse the progression of)]TJ
0 -1.1579 TD
0.011 Tw
[(overt clinical disease. Because the pathogenesis of )55(AD/dementia)]TJ
0 -1.15789 TD
0.166 Tw
(is believed to begin years before symptom expression and its)Tj
T*
-0.011 Tw
(onset is impossible to date, the lines between the state of normal,)Tj
0 -1.1579 TD
0.206 Tw
[(early and overt disease are imprecise. )55(At present the clinical)]TJ
0 -1.15789 TD
0.061 Tw
[(states of )55(AD/dementia and its expressed symptoms are the only)]TJ
0 -1.1579 TD
0.025 Tw
(available endpoints for prevention studies. )Tj
1.26316 -31.26315 TD
0.039 Tw
(The Figure presents the conceptual model of the relationship)Tj
-1.26316 -1.15789 TD
0.012 Tw
(between the clinical stages of disease development and the three)Tj
T*
0.02 Tc
0.365 Tw
(preventive approaches, set against the continuum of the)Tj
0 -1.1579 TD
0 Tc
0.314 Tw
(pathological process underlying dementia.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 209.8864 155.1577 Tm
0 0 0 1 k
(3)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 217.8569 152.0228 Tm
0 0 0 1 k
0.314 Tw
(At the induction)Tj
-18.71925 -1.15789 TD
0.148 Tw
(stage there are no clinical symptoms present despite the early)Tj
T*
-0.037 Tw
(subtle brain changes that are believed to occur in individuals who)Tj
0 -1.1579 TD
0.169 Tw
[(are eventually destined to develop the disease. )55(At the latency)]TJ
0 -1.15789 TD
0.239 Tw
(stage, there are clinical symptoms, currently known as Mild)Tj
T*
0.319 Tw
(Cognitive Impairment (MCI))Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 156.876 100.1578 Tm
0 0 0 1 k
(4)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 165.4124 97.0228 Tm
0 0 0 1 k
0.319 Tw
(or Cognitive Impairment Not)Tj
-13.19878 -1.1579 TD
0.205 Tw
(Dementia (CIND).)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 113.1809 89.1577 Tm
0 0 0 1 k
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 120.4655 86.0228 Tm
0 0 0 1 k
0.205 Tw
(These symptoms can be accompanied by)Tj
19.86258 66.32355 TD
0.334 Tw
(more defined pathological processes measurable on MRI,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 546.8585 719.2314 Tm
0 0 0 1 k
(6,7)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 309.16 705.0965 Tm
0 0 0 1 k
[(PET)74(,)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 327.7193 708.2314 Tm
0 0 0 1 k
(8)Tj
0.50001 -0.00001 TD
(,9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 339.8211 705.0965 Tm
0 0 0 1 k
0.199 Tw
[(and post-mortem neuropathology)65(.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 471.9886 708.2314 Tm
0 0 0 1 k
(1)Tj
0.5 -0.00001 TD
(0)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 482.3535 705.0965 Tm
0 0 0 1 k
0.199 Tw
(The percentage of)Tj
-18.23089 -1.15789 TD
0.291 Tw
[(MCI cases that advance to )55(AD/dementia is 10 to 15% per)]TJ
0 -1.1579 TD
0 Tw
(annum,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 337.391 686.2314 Tm
0 0 0 1 k
(1)Tj
0.44415 -0.00001 TD
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 348.7753 683.0964 Tm
0 0 0 1 k
0.325 Tw
(compared to 1 to 2% for normal subjects.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 527.6229 686.2314 Tm
0 0 0 1 k
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 536.2225 683.0964 Tm
0 0 0 1 k
(Mild)Tj
-23.90131 -1.15789 TD
0.1 Tw
(Cognitive Impairment is therefore an ideal stage for secondary)Tj
T*
0.02 Tc
0.539 Tw
[(preventive interventions. )18(Where MCI does advance to)]TJ
0 -1.1579 TD
0 Tc
-0.013 Tw
[(AD/dementia, the detection stage of diagnosable )55(AD/dementia is)]TJ
0 -1.15789 TD
0.02 Tc
0.722 Tw
(reached, with its pathological cascade of apoptosis,)Tj
T*
0 Tc
0.338 Tw
(inflammatory changes, increasing amyloidopathy and tangle)Tj
0 -1.1579 TD
0 Tw
(formation.)Tj
1.26316 -1.15789 TD
0.017 Tw
(There is an important current assumption underlying primary)Tj
-1.26316 -1.15789 TD
0.06 Tw
[(prevention of )55(AD/dementia. For successful prevention to occur)40(,)]TJ
0 -1.1579 TD
0.076 Tw
(the onset of the disease would have to be delayed in a sizeable)Tj
0 -1.15789 TD
0.207 Tw
(group of at-risk individuals some of whom will die of other)Tj
T*
0.114 Tw
[(causes prior to the diagnosable )55(AD/dementia state. It has been)]TJ
T*
-0.011 Tw
(calculated that interventions capable of producing even a modest)Tj
T*
0.3 Tw
[(delay in onset, such as 1 year)40(, would reduce )55(AD/dementia)]TJ
0 -1.1579 TD
0.06 Tw
(prevalence by 7% in 10 years and by 9% in 30 years. Delaying)Tj
0 -1.15789 TD
0.069 Tw
(the onset by 5 years could potentially reduce the prevalence by)Tj
0 -1.1579 TD
0.025 Tw
(40% in 10 years and by as much as 50% in 30 years.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 511.7097 510.2315 Tm
0 0 0 1 k
(12)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 485.0965 Tm
0 0 0 1 k
(H)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 316.5494 485.0965 Tm
0 0 0 1 k
0.004 Tc
[(OW)-327(T)21(O)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 344.3549 485.0965 Tm
0 0 0 1 k
(I)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 348.0496 485.0965 Tm
0 0 0 1 k
0.001 Tc
(DENTIFY)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 382.4585 485.0965 Tm
0 0 0 1 k
(C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 389.3168 485.0965 Tm
0 0 0 1 k
0.001 Tc
[(ANDIDA)75(T)-1(E)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 429.3964 485.0965 Tm
0 0 0 1 k
(I)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 433.0911 485.0965 Tm
0 0 0 1 k
0.001 Tc
[(NTER)36(VENTIONS)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 321.16 470.0965 Tm
0 0 0 1 k
0.032 Tw
[(Research on prevention of )55(AD/dementia has been \321and will)]TJ
-1.26316 -1.1579 TD
0.055 Tw
(likely continue to be\321 driven by evidence of protective factors)Tj
0 -1.15789 TD
0 Tw
(emer)Tj
1.98047 0 TD
-0.002 Tw
(ging from retrospective case-control and prospective cohort)Tj
-1.98047 -1.1579 TD
0.112 Tw
(studies of dementia. )Tj
8.55719 0 TD
(A)Tj
1.02932 0 TD
[(lar)18(ge number of medication, health and)]TJ
-9.5865 -1.1579 TD
0.196 Tw
(lifestyle factors including the use of statins,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 485.7164 429.2315 Tm
0 0 0 1 k
(13-15)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 504.5776 426.0965 Tm
0 0 0 1 k
(non-steroidal)Tj
-20.57027 -1.15789 TD
0.007 Tw
(anti-inflammatory (NSAID) drugs,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 441.9793 418.2315 Tm
0 0 0 1 k
(16,17)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 458.5316 415.0965 Tm
0 0 0 1 k
(vitamins,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 493.6255 418.2315 Tm
0 0 0 1 k
(18)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 502.3402 415.0965 Tm
0 0 0 1 k
(estrogens,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 540.5884 418.2315 Tm
0 0 0 1 k
(19,20)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 309.16 404.0965 Tm
0 0 0 1 k
0.02 Tc
0.371 Tw
(participation in cognitively demanding activities,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 519.26 407.2315 Tm
0 0 0 1 k
0.02 Tc
(21-23)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 540.5997 404.0965 Tm
0 0 0 1 k
0.02 Tc
(and)Tj
-24.36207 -1.1579 TD
0 Tc
0.053 Tw
(physical exercise,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 377.1811 396.2315 Tm
0 0 0 1 k
(24)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 386.329 393.0965 Tm
0 0 0 1 k
0.053 Tw
(have been associated with a reduced risk of)Tj
-8.12305 -1.15789 TD
0.019 Tc
0 Tw
(dementia. )Tj
4.69718 0 TD
0.356 Tw
(These associations suggest that a spectrum of)Tj
-4.69718 -1.1579 TD
0.02 Tc
0.857 Tw
(interventions \321pharmacological treatments, nutritional)Tj
T*
0.643 Tw
(supplements and lifestyle modifications\321 might have)Tj
0 -1.15789 TD
0 Tc
0.135 Tw
[(preventive ef)18(fects. However)39(, these association studies must be)]TJ
0 -1.1579 TD
0.136 Tw
[(tested through randomized controlled trials \(RCT)70(s\) before any)]TJ
T*
0.19 Tw
(intervention can be scientifically accepted and considered for)Tj
0 -1.15789 TD
0.006 Tc
0.369 Tw
(widespread application within the healthy population. )Tj
24.27866 0 TD
0 Tw
(The)Tj
-24.27866 -1.1579 TD
0 Tc
0.05 Tw
[(W)80(omen\325)55(s Health Initiative Memory Study (WHIMS) found that)]TJ
T*
0.02 Tc
0.431 Tw
(treatment with conjugated equine estrogen, alone or in)Tj
0 -1.15789 TD
0 Tc
0.036 Tw
(combination with medroxyprogesterone, was associated with an)Tj
T*
0.02 Tc
0.497 Tw
(increased risk of developing cognitive impairment and)Tj
0 -1.1579 TD
0 Tc
0 Tw
(dementia.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 346.3529 264.2314 Tm
0 0 0 1 k
(25,26)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 363.3794 261.0965 Tm
0 0 0 1 k
0.075 Tw
[(The )18(WHIMS outcome serves as a vivid reminder)]TJ
-5.70731 -1.15789 TD
0.02 Tc
0.456 Tw
(that factors identified as protective of )Tj
18.71541 0.00001 TD
(AD/dementia in)Tj
-18.71541 -1.1579 TD
0 Tc
0.137 Tw
(association studies do not necessarily have a preventive ef)Tj
24.34759 0.00001 TD
0 Tw
(fect)Tj
-24.34759 -1.15791 TD
0.025 Tw
[(when tested more definitively in an RCT)74(. )]TJ
1.26316 -1.15789 TD
0.18 Tw
(Beyond the epidemiological leads, the risk-benefit ratio of)Tj
-1.26316 -1.15789 TD
0.175 Tw
(candidate interventions must be carefully considered. Primary)Tj
0 -1.1579 TD
0.081 Tw
[(prevention interventions should be suf)18(ficiently safe to be given)]TJ
0 -1.15789 TD
-0.034 Tw
[(to healthy normal individuals without causing harm. )18(They should)]TJ
T*
0.089 Tw
[(be af)18(fordable such that widespread use can follow)65(. In addition,)]TJ
0 -1.1579 TD
-0.026 Tw
(compliance needs to be high and maintained over long periods of)Tj
0 -1.15789 TD
0.006 Tc
0.369 Tw
[(time. Lastly)65(, any such intervention should ideally have a)]TJ
T*
0.02 Tc
0.552 Tw
(biologically plausible mechanism of action within the)Tj
0 -1.1579 TD
0 Tc
0.025 Tw
[(framework of )55(AD/dementia pathogenesis. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 107.0965 Tm
0 0 0 1 k
(C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 316.0183 107.0965 Tm
0 0 0 1 k
0.001 Tc
(URRENT)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 348.5833 107.0965 Tm
0 0 0 1 k
(S)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 353.8644 107.0965 Tm
0 0 0 1 k
(T)Tj
0.59302 0.00001 TD
(A)Tj
0.64795 0.00001 TD
0.001 Tc
[(TUS)-365(O)-2(F)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 391.4198 107.0965 Tm
0 0 0 1 k
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 397.2228 107.0965 Tm
0 0 0 1 k
0.001 Tc
(RIMAR)Tj
3.46362 0.00001 TD
0 Tc
(Y)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 429.3947 107.0965 Tm
0 0 0 1 k
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 435.1977 107.0965 Tm
0 0 0 1 k
0.001 Tc
(REVENTION)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 480.8281 107.0965 Tm
0 0 0 1 k
(T)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 487.1645 107.0965 Tm
0 0 0 1 k
0.001 Tc
(RIALS)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 321.16 92.0965 Tm
0 0 0 1 k
0.013 Tc
0.362 Tw
[(T)70(o identify primary prevention RCT)70(s of )55(AD/dementia,)]TJ
-1.26316 -1.1579 TD
0 Tc
0.079 Tw
(PubMed and the US National Institutes of Health clinical trials)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
8.5 0 0 8.5 39.024 245.9677 Tm
0 0 0 1 k
(Figure:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
8.5 0 0 8.5 74.2441 245.9677 Tm
0 0 0 1 k
0.239 Tw
[(Pathogenesis, clinical states and pr)37(evention appr)37(oaches to)]TJ
-4.14354 -1.05882 TD
0 Tw
(AD/dementia.)Tj
ET
/GS2 gs
q
39.274 264.03 246.676 170.88 re
W n
/Fm0 Do
Q
/GS1 gs
0.5 w
0 0 0 1 K
39.274 264.03 246.676 170.88 re
s
Q
/GS2 gs
/GS1 gs
q
BT
/F9 1 Tf
5 0 0 5 45.5316 272.7259 Tm
0 0 0 1 k
0.028 Tw
(Adapted from Sano M. Noncholinergic treatment options for )Tj
26.78332 0.00001 TD
[(Alzheimer)-3718(s disease. J. Clin Psychiatry 2003: )]TJ
-18.10714 -1.20002 TD
[(64 Suppl 9:23-8. Reproduced with the permission of the publisher)55(.)]TJ
ET
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 39.024 29.4312 Tm
0 0 0 1 k
0.025 Tw
[(V)111(olume 34, Supplement No. 1 \320 Mar)37(ch 2007)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 540.0208 29.4312 Tm
0 0 0 1 k
(S85)Tj
ET
Q
endstream
endobj
26 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|]̗ǯḯr8 UaJ+sA1>Dcw#O*T V8Ux]t62;njn9=q5ُ.)VHcU$dO%EO
2ҴӤϘnĎcPv"WצUK7w
endstream
endobj
27 0 obj
<<
/Name /Fm0
/BBox [0 0 593.99994 782.99994]
/Subtype /Form
/Resources <<
/XObject <<
/Fm1 57 0 R
>>
/ProcSet [/PDF]
/ExtGState <<
/GS3 58 0 R
>>
>>
/Type /XObject
/Length 62
/Matrix [1 0 0 1 0 0]
/OPI <<
/1.3 <<
/CropFixed [86.348 498.431 1950 1792.93506]
/Resolution [300 300]
/ImageType [1 8]
/Position [39.274 264.03 39.274 434.91 284.37299 434.91 284.37299 264.03]
/Overprint false
/ColorType /Process
/F (Production Archives:Production archive: Journal Old issues:33SUPPLEMENTS:DEMENTIA SUPPLEMENT:Figures:2946 figure.tif)
/Color [0 0 0 1 (Black)]
/CropRect [86 498 1950 1793]
/Size [1950 2059]
/Version 1.3
/Type /OPI
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
245.2764 0 0 171.32111 39.097 263.7849 cm
/Fm1 Do
Q
endstream
endobj
28 0 obj
<<
/LastChar 213
/FirstChar 32
/FontDescriptor 59 0 R
/Widths [278 0 0 0 0 0 0 0 0 0
0 0 0 333 278 0 556 0 556 556
556 0 556 0 556 556 278 0 0 0
0 0 0 667 0 722 0 0 0 0
0 0 500 0 0 833 722 0 667 0
722 667 0 0 0 0 0 0 0 0
0 0 0 0 0 556 556 500 556 556
278 556 556 222 0 0 222 833 556 556
556 0 333 500 278 556 0 722 0 500
500 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 222]
/Encoding 60 0 R
/Subtype /Type1
/BaseFont /QRNEIP+Helvetica
/Name /F9
/Type /Font
>>
endobj
29 0 obj
<<
/LastChar 122
/FirstChar 32
/FontDescriptor 61 0 R
/Widths [250 0 0 0 0 0 0 0 333 333
0 0 0 0 0 278 0 500 500 500
500 500 0 0 0 0 333 0 0 0
0 0 0 667 0 0 722 0 667 0
778 0 0 0 0 0 0 0 611 0
667 556 611 0 0 0 0 0 0 0
0 0 0 0 0 500 0 444 500 444
333 500 556 278 278 0 278 778 556 500
500 0 389 389 278 556 444 0 0 444
389]
/Encoding 62 0 R
/Subtype /Type1
/BaseFont /FLDMAH+Times-BoldItalic
/Name /F8
/Type /Font
>>
endobj
30 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 63 0 R
>>
endobj
31 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
32 0 obj
<<
/Length 29354
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
39.696 726 516 30 re
f
Q
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 749.8455 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)]TJ
-2.21865 -80.04603 TD
0 Tw
(S86)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 717.024 Tm
0 0 0 1 k
0.214 Tw
[(web site \(www)65(.ClinicalT)35(rials.gov\) were searched. )17(The search)]TJ
0 -1.1579 TD
-0.016 Tw
[(yielded eight primary prevention RCT)70(s summarized in the )17(T)70(able.)]TJ
0 -1.15789 TD
0.02 Tc
0.359 Tw
[(These trials address the ef)18(ficacy and safety of NSAIDs)]TJ
T*
0 Tc
0.333 Tw
(\(Naproxen and Celecoxib\), hormonal therapy \(estrogen and)Tj
0 -1.1579 TD
0.242 Tw
(progesterone\), antihypertensive drugs \(Nitrendipine, Enalapril)Tj
0 -1.15789 TD
-0.0001 Tc
(a)Tj
0.44391 -0.00001 TD
(nd)Tj
1.52597 0 Td
0 Tc
0.276 Tw
(Hydrochlorothiazide; Candesartan\), antioxidants \(Ginkgo)Tj
-1.96988 -1.15789 TD
0.012 Tc
0.363 Tw
[(Biloba\) and supplements \(V)60(itamin E and Selenium\). )17(The)]TJ
T*
0 Tc
0.166 Tw
(antihypertensive drug trials (Syst-Eur and SCOPE) have been)Tj
0 -1.1579 TD
0.371 Tw
(completed, with mixed results. In Syst-Eur a reduction in)Tj
0 -1.15789 TD
-0.006 Tw
(dementia incidence was observed in the treated group,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 245.8623 621.159 Tm
0 0 0 1 k
(27)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 254.446 618.024 Tm
0 0 0 1 k
(whereas)Tj
-22.57074 -1.15789 TD
0.021 Tw
[(in SCOPE there was no dif)18(ference in incident cases between the)]TJ
0 -1.1579 TD
0.04 Tw
(treated and control group.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 139.2844 599.159 Tm
0 0 0 1 k
(28)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 148.1388 596.024 Tm
0 0 0 1 k
0.04 Tw
[(Three RCT)70(s \(ADAPT)74(, )17(WHIMS and)]TJ
-11.3805 -1.15789 TD
0.011 Tc
0.364 Tw
[(PREP)92(ARE\) have been halted because of emer)17(ging safety)]TJ
T*
0 Tc
0.022 Tw
[(concerns. )55(ADAPT)-254(was discontinued for reasons of unacceptable)]TJ
0 -1.1579 TD
-0.027 Tw
[(toxicity)65(, where a risk of cardiovascular events in association with)]TJ
0 -1.15789 TD
0.02 Tc
0.411 Tw
(naproxen arose.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 106.9076 555.159 Tm
0 0 0 1 k
0.02 Tc
(29)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 119.7248 552.024 Tm
0 0 0 1 k
0.02 Tc
0.411 Tw
[(The )18(WHIMS and PREP)91(ARE trials of)]TJ
-8.38956 -1.15789 TD
0.005 Tc
0.37 Tw
(conjugated equine estrogen alone, or in combination with)Tj
28.33011 18.52618 TD
0.003 Tc
0.372 Tw
(medroxyprogesterone acetate, have been halted because of)Tj
0 -1.15789 TD
0 Tc
0.1 Tw
(increased risks of breast cancer and cardiovascular problems.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 548.4259 709.1578 Tm
0 0 0 1 k
(25)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 309.16 695.0228 Tm
0 0 0 1 k
(GEMS,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 337.9221 698.1578 Tm
0 0 0 1 k
(3)Tj
0.5 -0.00001 TD
(0)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 348.2035 695.0228 Tm
0 0 0 1 k
(GuidAge,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 385.401 698.1578 Tm
0 0 0 1 k
(3)Tj
0.5 -0.00001 TD
(1)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 395.6823 695.0228 Tm
0 0 0 1 k
0.172 Tw
(and PREADVISE)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 465.6509 698.1578 Tm
0 0 0 1 k
(3)Tj
0.5 -0.00001 TD
(2)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 475.9323 695.0228 Tm
0 0 0 1 k
0.172 Tw
(are in process, with)Tj
-17.55498 -1.1579 TD
0.025 Tw
(results not anticipated for some considerable length of time. )Tj
1.26316 -1.15789 TD
0.07 Tw
(This first generation of trials does not address the full range)Tj
-1.26316 -1.15789 TD
0.345 Tw
[(of potentially ef)18(ficacious preventive strategies. Of potential)]TJ
0 -1.1579 TD
0.092 Tw
(interest for future primary prevention trials will be agents with)Tj
0 -1.15789 TD
0.017 Tc
0.358 Tw
(anti-amyloidogenic action, hyperlipidaemia-lowering drugs)Tj
T*
0.02 Tc
0.645 Tw
(including statins,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 383.6159 632.1578 Tm
0 0 0 1 k
0.02 Tc
(33,34)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 407.0428 629.0228 Tm
0 0 0 1 k
0.02 Tc
0.645 Tw
(and agents capable of reducing)Tj
-10.30345 -1.1579 TD
0 Tc
0.025 Tw
[(hyperhomocysteinemia, neuronal DNA)-220(damage and apoptosis.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 548.0355 621.1578 Tm
0 0 0 1 k
(3)Tj
0.5 -0.00001 TD
(5)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 596.0228 Tm
0 0 0 1 k
(D)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 316.0183 596.0228 Tm
0 0 0 1 k
0.0014 Tc
(E)Tj
0.66739 -0.00001 TD
0.001 Tc
[(SIGN)-677(AND)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 363.6713 596.0228 Tm
0 0 0 1 k
(M)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 372.6378 596.0228 Tm
0 0 0 1 k
0.0014 Tc
(E)Tj
0.6674 -0.00001 TD
0.001 Tc
(THODOLOGICAL)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 442.3898 596.0228 Tm
0 0 0 1 k
(C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 449.2481 596.0228 Tm
0 0 0 1 k
0.0013 Tc
(H)Tj
0.77729 -0.00001 TD
0.001 Tc
[(ALLENGES)-732(F)-1(O)-1(R)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 519.0711 596.0228 Tm
0 0 0 1 k
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 524.874 596.0228 Tm
0 0 0 1 k
0.0014 Tc
(R)Tj
0.72238 -0.00001 TD
0.001 Tc
[(IMAR)36(Y)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 585.0228 Tm
0 0 0 1 k
(P)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 314.963 585.0228 Tm
0 0 0 1 k
0.001 Tc
(REVENTION)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 360.7204 585.0228 Tm
0 0 0 1 k
0.001 Tc
(RCT)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 380.7733 585.0228 Tm
0 0 0 1 k
(S)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 321.16 570.0228 Tm
0 0 0 1 k
-0.018 Tw
[(Prevention RCT)70(s face unique challenges, some of which have)]TJ
-1.26316 -1.15789 TD
0.025 Tw
[(already emer)18(ged from the first generation of trials.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9.5 0 0 9.5 309.16 548.0228 Tm
0 0 0 1 k
0.291 Tw
((1) Sample sizes and costs:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 429.3246 548.0228 Tm
0 0 0 1 k
0.291 Tw
[(As seen in the )18(T)70(able, primary)]TJ
-12.6489 -1.1579 TD
0.082 Tw
[(prevention RCT)70(s have required very lar)17(ge sample sizes \(n=900)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 477.7555 Tm
0 0 0 1 k
0.001 Tc
0.025 Tw
[(T)92(able: Placebo-contr)18(olled )56(AD/dementia pr)19(evention RCT)93(s (ongoing and completed))]TJ
ET
1 w
0 0 0 1 K
39.024 69.21 m
554.976 69.21 l
S
39.024 491.317 m
554.976 491.317 l
S
0.5 w
39.024 458.317 m
554.976 458.317 l
S
/GS2 gs
q
39.024 69.513 m
39.024 453.725 l
554.976 453.725 l
554.976 69.513 l
W n
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 446.1896 Tm
0 g
0.0338 Tc
(T)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 43.5291 446.1896 Tm
1 Tr
0 G
0 Tc
(T)Tj
0.69077 0 Td
0 Tr
0.0338 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.43784 0 Td
0 Tr
0.0338 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.35079 0 Td
0 Tr
0.0338 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.59077 0 Td
0 Tr
0.0338 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
-2.07016 -1.24324 TD
0 Tr
0.0304 Tc
(\()Tj
0 0 Td
1 Tr
0 Tc
(\()Tj
0.35045 0 Td
0 Tr
0.0304 Tc
(A)Tj
0 0 Td
1 Tr
0 Tc
(A)Tj
0.72038 0 Td
0 Tr
0.0304 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.45338 0 Td
0 Tr
0.0304 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.43446 0 Td
0 Tr
0.0304 Tc
(o)Tj
0 0 Td
1 Tr
0 Tc
(o)Tj
0.53232 0 Td
0 Tr
0.0304 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59549 0 Td
0 Tr
0.0304 Tc
(y)Tj
0 0 Td
1 Tr
0 Tc
(y)Tj
0.49336 0 Td
0 Tr
0.0304 Tc
(m)Tj
0 0 Td
1 Tr
0 Tc
(m)Tj
0.87038 0 Td
0 Tr
0.0304 Tc
(\))Tj
0 0 Td
1 Tr
0 Tc
(\))Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 446.1896 Tm
0 g
0.0324 Tc
(S)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 107.3691 446.1896 Tm
1 Tr
0 G
0 Tc
(S)Tj
0.55147 0 Td
0 Tr
0.0324 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37635 0 Td
0 Tr
0.0324 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.58953 0 Td
0 Tr
0.0324 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37635 0 Td
0 Tr
0.0324 Tc
(u)Tj
0 0 Td
1 Tr
0 Tc
(u)Tj
0.61644 0 Td
0 Tr
0.0324 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 446.1896 Tm
0 g
0.0295 Tc
(I)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 175.0491 446.1896 Tm
1 Tr
0 G
0 Tc
(I)Tj
0.39144 0 Td
0 Tr
0.0295 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59448 0 Td
0 Tr
0.0295 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37354 0 Td
0 Tr
0.0295 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47252 0 Td
0 Tr
0.0295 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.43344 0 Td
0 Tr
0.0295 Tc
(v)Tj
0 0 Td
1 Tr
0 Tc
(v)Tj
0.4955 0 Td
0 Tr
0.0295 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47241 0 Td
0 Tr
0.0295 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59459 0 Td
0 Tr
0.0295 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37342 0 Td
0 Tr
0.0295 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34651 0 Td
0 Tr
0.0295 Tc
(o)Tj
0 0 Td
1 Tr
0 Tc
(o)Tj
0.53142 0 Td
0 Tr
0.0295 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 446.1896 Tm
0 g
0.0177 Tc
(S)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 269.3691 446.1896 Tm
1 Tr
0 G
0 Tc
(S)Tj
0.53671 0 Td
0 Tr
0.0177 Tc
(u)Tj
0 0 Td
1 Tr
0 Tc
(u)Tj
0.60158 0 Td
0 Tr
0.0177 Tc
(b)Tj
0 0 Td
1 Tr
0 Tc
(b)Tj
0.55371 0 Td
0 Tr
0.0177 Tc
(j)Tj
0 0 Td
1 Tr
0 Tc
(j)Tj
0.29764 0 Td
0 Tr
0.0177 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.4607 0 Td
0 Tr
0.0177 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.44065 0 Td
0 Tr
0.0177 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.78525 0 Td
0 Tr
0.0177 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
0.3946 0 Td
0 Tr
0.0177 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.4607 0 Td
0 Tr
0.0177 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
0.32365 0 Td
0 Tr
0.0177 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.4607 0 Td
0 Tr
0.0177 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.44065 0 Td
0 Tr
0.0177 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.36171 0 Td
0 Tr
0.0177 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.33468 0 Td
0 Tr
0.0177 Tc
(o)Tj
0 0 Td
1 Tr
0 Tc
(o)Tj
0.51971 0 Td
0 Tr
0.0177 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
-6.97263 -1.24324 TD
0 Tr
0.0309 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.45394 0 Td
0 Tr
0.0309 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.4348 0 Td
0 Tr
0.0309 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34797 0 Td
0 Tr
0.0309 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37489 0 Td
0 Tr
0.0309 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47388 0 Td
0 Tr
0.0309 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.4348 0 Td
0 Tr
0.0309 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34797 0 Td
0 Tr
0.0309 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
ET
Q
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 446.1896 Tm
0 g
0.0315 Tc
(D)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 386.4891 446.1896 Tm
1 Tr
0 G
0 Tc
(D)Tj
0.77556 0 Td
0 Tr
0.0315 Tc
(u)Tj
0 0 Td
1 Tr
0 Tc
(u)Tj
0.61554 0 Td
0 Tr
0.0315 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.43548 0 Td
0 Tr
0.0315 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.58851 0 Td
0 Tr
0.0315 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37556 0 Td
0 Tr
0.0315 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34853 0 Td
0 Tr
0.0315 Tc
(o)Tj
0 0 Td
1 Tr
0 Tc
(o)Tj
-3.13919 -1.24324 TD
0 Tr
0.0135 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.95619 0 Td
0 Tr
0.0135 Tc
(\()Tj
0 0 Td
1 Tr
0 Tc
(\()Tj
0.33356 0 Td
0 Tr
0.0135 Tc
(y)Tj
0 0 Td
1 Tr
0 Tc
(y)Tj
0.47647 0 Td
0 Tr
0.0135 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.45653 0 Td
0 Tr
0.0135 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.5705 0 Td
0 Tr
0.0135 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.41756 0 Td
0 Tr
0.0135 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
0.39043 0 Td
0 Tr
0.0135 Tc
(\))Tj
0 0 Td
1 Tr
0 Tc
(\))Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 446.1896 Tm
0 g
0.0315 Tc
(O)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 440.4891 446.1896 Tm
1 Tr
0 G
0 Tc
(O)Tj
0.78153 0 Td
0 Tr
0.0315 Tc
(v)Tj
0 0 Td
1 Tr
0 Tc
(v)Tj
0.49752 0 Td
0 Tr
0.0315 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47456 0 Td
0 Tr
0.0315 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.43547 0 Td
0 Tr
0.0315 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.58863 0 Td
0 Tr
0.0315 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
0.3375 0 Td
0 Tr
0.0315 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
-3.1152 -1.24324 TD
0 Tr
0.0304 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47343 0 Td
0 Tr
0.0304 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
0.40743 0 Td
0 Tr
0.0304 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37432 0 Td
0 Tr
0.0304 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34741 0 Td
0 Tr
0.0304 Tc
(m)Tj
0 0 Td
1 Tr
0 Tc
(m)Tj
0.87038 0 Td
0 Tr
0.0304 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.5875 0 Td
0 Tr
0.0304 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.37432 0 Td
0 Tr
0.0304 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47343 0 Td
0 Tr
0.0304 Tc
(d)Tj
0 0 Td
1 Tr
0 Tc
(d)Tj
-3.90823 -1.24325 TD
0 Tr
0.0304 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34741 0 Td
0 Tr
0.0304 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59538 0 Td
0 Tr
0.0304 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.45338 0 Td
0 Tr
0.0304 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.34741 0 Td
0 Tr
0.0304 Tc
(d)Tj
0 0 Td
1 Tr
0 Tc
(d)Tj
0.60045 0 Td
0 Tr
0.0304 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47342 0 Td
0 Tr
0.0304 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59538 0 Td
0 Tr
0.0304 Tc
(c)Tj
0 0 Td
1 Tr
0 Tc
(c)Tj
0.45338 0 Td
0 Tr
0.0304 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
-3.86622 -1.21622 TD
0 Tr
0.0118 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.41577 0 Td
0 Tr
0.0118 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.56892 0 Td
0 Tr
0.0118 Tc
(t)Tj
0 0 Td
1 Tr
0 Tc
(t)Tj
0.35574 0 Td
0 Tr
0.0118 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.81385 0 Td
0 Tr
0.0118 Tc
(\()Tj
0 0 Td
1 Tr
0 Tc
(\()Tj
0.33187 0 Td
0 Tr
0.0118 Tc
(%)Tj
0 0 Td
1 Tr
0 Tc
(%)Tj
-2.48615 -1.24324 TD
0 Tr
0.0127 Tc
(p)Tj
0 0 Td
1 Tr
0 Tc
(p)Tj
0.56667 0 Td
0 Tr
0.0127 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.45574 0 Td
0 Tr
0.0127 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
0.7857 0 Td
0 Tr
0.0127 Tc
(y)Tj
0 0 Td
1 Tr
0 Tc
(y)Tj
0.47568 0 Td
0 Tr
0.0127 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.45574 0 Td
0 Tr
0.0127 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.56971 0 Td
0 Tr
0.0127 Tc
(r)Tj
0 0 Td
1 Tr
0 Tc
(r)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 446.1896 Tm
0 g
0.0315 Tc
(P)Tj
ET
1.02 0 0 1 0 0 cm
0.2131 w
BT
/F10 1 Tf
8.88 0 0 8.88 499.0491 446.1896 Tm
1 Tr
0 G
0 Tc
(P)Tj
0.62951 0 Td
0 Tr
0.0315 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
0.33761 0 Td
0 Tr
0.0315 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.58851 0 Td
0 Tr
0.0315 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59651 0 Td
0 Tr
0.0315 Tc
(n)Tj
0 0 Td
1 Tr
0 Tc
(n)Tj
0.59651 0 Td
0 Tr
0.0315 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
0.47455 0 Td
0 Tr
0.0315 Tc
(d)Tj
0 0 Td
1 Tr
0 Tc
(d)Tj
-3.2232 -1.24324 TD
0 Tr
0.0324 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
0.40946 0 Td
0 Tr
0.0324 Tc
(a)Tj
0 0 Td
1 Tr
0 Tc
(a)Tj
0.58941 0 Td
0 Tr
0.0324 Tc
(m)Tj
0 0 Td
1 Tr
0 Tc
(m)Tj
0.87241 0 Td
0 Tr
0.0324 Tc
(p)Tj
0 0 Td
1 Tr
0 Tc
(p)Tj
0.58648 0 Td
0 Tr
0.0324 Tc
(l)Tj
0 0 Td
1 Tr
0 Tc
(l)Tj
0.3384 0 Td
0 Tr
0.0324 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
-2.79617 -1.24325 TD
0 Tr
0.036 Tc
(s)Tj
0 0 Td
1 Tr
0 Tc
(s)Tj
0.41306 0 Td
0 Tr
0.036 Tc
(i)Tj
0 0 Td
1 Tr
0 Tc
(i)Tj
0.35305 0 Td
0 Tr
0.036 Tc
(z)Tj
0 0 Td
1 Tr
0 Tc
(z)Tj
0.48299 0 Td
0 Tr
0.036 Tc
(e)Tj
0 0 Td
1 Tr
0 Tc
(e)Tj
ET
Q
q
0 g
103.8861 388.5896 0.4896 66 re
f
172.6749 388.5896 0.4896 66 re
f
269.1261 388.5896 0.4896 66 re
f
388.3437 388.5896 0.4896 66 re
f
443.4237 388.5896 0.4896 66 re
f
503.1549 388.5896 0.4896 66 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 379.7096 Tm
0 Tc
0 Tw
(PREPARE)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 379.7096 Tm
0 Tc
0 Tw
(Discontinued)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 379.7096 Tm
0 Tc
0 Tw
(Conjugated equine)Tj
0 -1.24325 TD
(estrogen alone)Tj
0 -1.24324 TD
(Conj. equ. estrogen +)Tj
T*
(medroxyprogesterone)Tj
0 -1.21623 TD
(acetate)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 379.7096 Tm
0 Tc
0 Tw
(Female sex)Tj
0 -1.24325 TD
(Family history of AD)Tj
0 -1.24324 TD
(Age > 65)Tj
ET
Q
291.1581 356.1896 5.6304 0.48 re
f
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 379.7096 Tm
0 Tc
(3)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 379.7096 Tm
0 Tc
(5)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 379.7096 Tm
0 Tc
0 Tw
(900)Tj
ET
Q
39.0141 388.1096 64.872 0.48 re
f
103.8861 388.1096 0.4896 0.48 re
f
104.3757 388.1096 68.2992 0.48 re
f
172.6749 388.1096 0.4896 0.48 re
f
173.1645 388.1096 95.9616 0.48 re
f
269.1261 388.1096 0.4896 0.48 re
f
269.6157 388.1096 118.728 0.48 re
f
388.3437 388.1096 0.4896 0.48 re
f
388.8333 388.1096 54.5904 0.48 re
f
443.4237 388.1096 0.4896 0.48 re
f
443.9133 388.1096 59.2416 0.48 re
f
503.1549 388.1096 0.4896 0.48 re
f
503.6445 388.1096 54.5904 0.48 re
f
103.8861 333.1496 0.4896 54.96 re
f
172.6749 333.1496 0.4896 54.96 re
f
269.1261 333.1496 0.4896 54.96 re
f
388.3437 333.1496 0.4896 54.96 re
f
443.4237 333.1496 0.4896 54.96 re
f
503.1549 333.1496 0.4896 54.96 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 324.2696 Tm
0 Tc
0 Tw
(ADAPT)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 324.2696 Tm
0 Tc
0 Tw
(Discontinued)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 324.2696 Tm
0 Tc
0 Tw
(Naproxen or)Tj
0 -1.24325 TD
(Celecoxib)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 324.2696 Tm
0 Tc
0 Tw
(Family history of dementia)Tj
0 -1.24325 TD
(Age > 70)Tj
ET
Q
291.1581 311.7896 5.6304 0.48 re
f
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 324.2696 Tm
0 Tc
(5)Tj
0.758 0 Td
Tj
0.836 0 Td
(7)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 324.2696 Tm
0 Tc
(3)Tj
0.758 0 Td
(-)Tj
0.594 0 Td
0 Tw
(3.4)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 324.2696 Tm
0 Tc
0 Tw
(2,800)Tj
ET
Q
39.0141 332.6696 64.872 0.48 re
f
103.8861 332.6696 0.4896 0.48 re
f
104.3757 332.6696 68.2992 0.48 re
f
172.6749 332.6696 0.4896 0.48 re
f
173.1645 332.6696 95.9616 0.48 re
f
269.1261 332.6696 0.4896 0.48 re
f
269.6157 332.6696 118.728 0.48 re
f
388.3437 332.6696 0.4896 0.48 re
f
388.8333 332.6696 54.5904 0.48 re
f
443.4237 332.6696 0.4896 0.48 re
f
443.9133 332.6696 59.2416 0.48 re
f
503.1549 332.6696 0.4896 0.48 re
f
503.6445 332.6696 54.5904 0.48 re
f
103.8861 299.5496 0.4896 33.12 re
f
172.6749 299.5496 0.4896 33.12 re
f
269.1261 299.5496 0.4896 33.12 re
f
388.3437 299.5496 0.4896 33.12 re
f
443.4237 299.5496 0.4896 33.12 re
f
503.1549 299.5496 0.4896 33.12 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 290.6696 Tm
0 Tc
0 Tw
(SYST-EUR)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 290.6696 Tm
0 Tc
0 Tw
(Completed)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 290.6696 Tm
0 Tc
0 Tw
(Nitrendipine and/or)Tj
0 -1.24324 TD
(Enalapril and/or)Tj
T*
(Hydrocholorthiazide)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 290.6696 Tm
0 Tc
0 Tw
(Systolic hypertension)Tj
0 -1.24324 TD
(Age > 60)Tj
ET
Q
291.1581 278.1896 5.6304 0.48 re
f
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 290.6696 Tm
0 Tc
(5)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 290.6696 Tm
0 Tc
0 Tw
(1.6)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 290.6696 Tm
0 Tc
0 Tw
(3,000)Tj
ET
Q
39.0141 299.0696 64.872 0.48 re
f
103.8861 299.0696 0.4896 0.48 re
f
104.3757 299.0696 68.2992 0.48 re
f
172.6749 299.0696 0.4896 0.48 re
f
173.1645 299.0696 95.9616 0.48 re
f
269.1261 299.0696 0.4896 0.48 re
f
269.6157 299.0696 118.728 0.48 re
f
388.3437 299.0696 0.4896 0.48 re
f
388.8333 299.0696 54.5904 0.48 re
f
443.4237 299.0696 0.4896 0.48 re
f
443.9133 299.0696 59.2416 0.48 re
f
503.1549 299.0696 0.4896 0.48 re
f
503.6445 299.0696 54.5904 0.48 re
f
103.8861 255.1496 0.4896 43.92 re
f
172.6749 255.1496 0.4896 43.92 re
f
269.1261 255.1496 0.4896 43.92 re
f
388.3437 255.1496 0.4896 43.92 re
f
443.4237 255.1496 0.4896 43.92 re
f
503.1549 255.1496 0.4896 43.92 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 246.2696 Tm
0 Tc
(SCOPE)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 246.2696 Tm
0 Tc
0 Tw
(Completed)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 246.2696 Tm
0 Tc
0 Tw
(Candesartan cilexetil)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 246.2696 Tm
0 Tc
0 Tw
(Systolic hypertension)Tj
0 -1.24325 TD
(Age 70 to 89)Tj
ET
Q
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 246.2696 Tm
0 Tc
(3)Tj
0.758 0 Td
(-)Tj
0.594 0 Td
(5)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 246.2696 Tm
0 Tc
0 Tw
(2.4)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 246.2696 Tm
0 Tc
0 Tw
(4,000)Tj
ET
Q
39.0141 254.6696 64.872 0.48 re
f
103.8861 254.6696 0.4896 0.48 re
f
104.3757 254.6696 68.2992 0.48 re
f
172.6749 254.6696 0.4896 0.48 re
f
173.1645 254.6696 95.9616 0.48 re
f
269.1261 254.6696 0.4896 0.48 re
f
269.6157 254.6696 118.728 0.48 re
f
388.3437 254.6696 0.4896 0.48 re
f
388.8333 254.6696 54.5904 0.48 re
f
443.4237 254.6696 0.4896 0.48 re
f
443.9133 254.6696 59.2416 0.48 re
f
503.1549 254.6696 0.4896 0.48 re
f
503.6445 254.6696 54.5904 0.48 re
f
103.8861 221.5496 0.4896 33.12 re
f
172.6749 221.5496 0.4896 33.12 re
f
269.1261 221.5496 0.4896 33.12 re
f
388.3437 221.5496 0.4896 33.12 re
f
443.4237 221.5496 0.4896 33.12 re
f
503.1549 221.5496 0.4896 33.12 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 212.6696 Tm
0 Tc
0 Tw
(GEMS)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 212.6696 Tm
0 Tc
0 Tw
(Ongoing)Tj
0 -1.24325 TD
(extended)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 212.6696 Tm
0 Tc
0 Tw
(Ginkgo biloba)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 212.6696 Tm
0 Tc
0 Tw
(Age > 75 \( >)Tj
ET
Q
291.1581 211.2296 5.6304 0.48 re
f
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 323.0979 212.6696 Tm
0 Tc
0 Tw
(71 if of African)Tj
ET
Q
315.3932 211.2296 5.6304 0.48 re
f
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 201.6296 Tm
0 Tc
0 Tw
(ancestry\))Tj
ET
Q
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 212.6696 Tm
0 Tc
(5)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 212.6696 Tm
0 Tc
(4)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 212.6696 Tm
0 Tc
0 Tw
(3,000)Tj
ET
Q
39.0141 221.0696 64.872 0.48 re
f
103.8861 221.0696 0.4896 0.48 re
f
104.3757 221.0696 68.2992 0.48 re
f
172.6749 221.0696 0.4896 0.48 re
f
173.1645 221.0696 95.9616 0.48 re
f
269.1261 221.0696 0.4896 0.48 re
f
269.6157 221.0696 118.728 0.48 re
f
388.3437 221.0696 0.4896 0.48 re
f
388.8333 221.0696 54.5904 0.48 re
f
443.4237 221.0696 0.4896 0.48 re
f
443.9133 221.0696 59.2416 0.48 re
f
503.1549 221.0696 0.4896 0.48 re
f
503.6445 221.0696 54.5904 0.48 re
f
103.8861 187.9496 0.4896 33.12 re
f
172.6749 187.9496 0.4896 33.12 re
f
269.1261 187.9496 0.4896 33.12 re
f
388.3437 187.9496 0.4896 33.12 re
f
443.4237 187.9496 0.4896 33.12 re
f
503.1549 187.9496 0.4896 33.12 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 179.3096 Tm
0 Tc
0 Tw
(GUIDAGE)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 179.3096 Tm
0 Tc
0 Tw
(Ongoing)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 179.3096 Tm
0 Tc
0 Tw
(Ginkgo biloba)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 179.3096 Tm
0 Tc
0 Tw
(Age > 70)Tj
ET
Q
291.1581 177.8696 5.6304 0.48 re
f
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 168.2696 Tm
0 Tc
0 Tw
(Memory complaints)Tj
ET
Q
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 179.3096 Tm
0 Tc
(5)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 179.3096 Tm
0 Tc
0 Tw
(Not)Tj
0 -1.24324 TD
(available)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 179.3096 Tm
0 Tc
0 Tw
(2,800)Tj
ET
Q
39.0141 187.4696 64.872 0.48 re
f
103.8861 187.4696 0.4896 0.48 re
f
104.3757 187.4696 68.2992 0.48 re
f
172.6749 187.4696 0.4896 0.48 re
f
173.1645 187.4696 95.9616 0.48 re
f
269.1261 187.4696 0.4896 0.48 re
f
269.6157 187.4696 118.728 0.48 re
f
388.3437 187.4696 0.4896 0.48 re
f
388.8333 187.4696 54.5904 0.48 re
f
443.4237 187.4696 0.4896 0.48 re
f
443.9133 187.4696 59.2416 0.48 re
f
503.1549 187.4696 0.4896 0.48 re
f
503.6445 187.4696 54.5904 0.48 re
f
103.8861 154.5896 0.4896 32.88 re
f
172.6749 154.5896 0.4896 32.88 re
f
269.1261 154.5896 0.4896 32.88 re
f
388.3437 154.5896 0.4896 32.88 re
f
443.4237 154.5896 0.4896 32.88 re
f
503.1549 154.5896 0.4896 32.88 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 145.7096 Tm
0 Tc
0 Tw
(WHIMS)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 145.7096 Tm
0 Tc
0 Tw
(Discontinued)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 145.7096 Tm
0 Tc
0 Tw
(Conjugated equine)Tj
0 -1.24324 TD
(estrogen alone)Tj
0 -1.24325 TD
(Conj. equ. estrogen +)Tj
0 -1.24324 TD
(medroxyprogesterone)Tj
0 -1.21621 TD
(acetate)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 145.7096 Tm
0 Tc
0 Tw
(Female sex)Tj
0 -1.24324 TD
(Age > 65)Tj
ET
Q
291.1581 133.2296 5.6304 0.48 re
f
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 145.7096 Tm
0 Tc
(6)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 145.7096 Tm
0 Tc
(2)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 145.7096 Tm
0 Tc
0 Tw
(8,300)Tj
ET
Q
39.0141 154.1096 64.872 0.48 re
f
103.8861 154.1096 0.4896 0.48 re
f
104.3757 154.1096 68.2992 0.48 re
f
172.6749 154.1096 0.4896 0.48 re
f
173.1645 154.1096 95.9616 0.48 re
f
269.1261 154.1096 0.4896 0.48 re
f
269.6157 154.1096 118.728 0.48 re
f
388.3437 154.1096 0.4896 0.48 re
f
388.8333 154.1096 54.5904 0.48 re
f
443.4237 154.1096 0.4896 0.48 re
f
443.9133 154.1096 59.2416 0.48 re
f
503.1549 154.1096 0.4896 0.48 re
f
503.6445 154.1096 54.5904 0.48 re
f
103.8861 99.1496 0.4896 54.96 re
f
172.6749 99.1496 0.4896 54.96 re
f
269.1261 99.1496 0.4896 54.96 re
f
388.3437 99.1496 0.4896 54.96 re
f
443.4237 99.1496 0.4896 54.96 re
f
503.1549 99.1496 0.4896 54.96 re
f
q
39.0141 -242.8504 64.872 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 44.3997 90.2696 Tm
0 Tc
0 Tw
(PREADVISE)Tj
ET
Q
q
104.3757 -242.8504 68.2992 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 109.5165 90.2696 Tm
0 Tc
0 Tw
(Ongoing)Tj
ET
Q
q
173.1645 -242.8504 95.9616 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 178.5501 90.2696 Tm
0 Tc
0 Tw
(Vitamin E or)Tj
0 -1.24324 TD
(Selenium or Both)Tj
ET
Q
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 90.2696 Tm
0 Tc
0 Tw
[(Age > 62 \()-14(>)]TJ
ET
Q
291.1581 88.8296 5.6304 0.48 re
f
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 321.1395 90.2696 Tm
0 Tc
0 Tw
(60 if of African)Tj
ET
Q
313.4349 88.8296 5.6304 0.48 re
f
q
269.6157 -242.8504 118.728 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 274.7565 79.2296 Tm
0 Tc
0 Tw
(or Hispanic ancestry\))Tj
ET
Q
q
388.8333 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 394.2189 90.2696 Tm
0 Tc
0 Tw
(9-12)Tj
ET
Q
q
443.9133 -242.8504 59.2416 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 449.2989 90.2696 Tm
0 Tc
(1)Tj
ET
Q
q
503.6445 -242.8504 54.5904 733.92 re
W n
BT
/F10 1 Tf
9.0576 0 0 8.88 509.0301 90.2696 Tm
0 Tc
0 Tw
(10,700)Tj
ET
Q
39.0141 98.6696 64.872 0.48 re
f
103.8861 98.6696 0.4896 0.48 re
f
104.3757 98.6696 68.2992 0.48 re
f
172.6749 98.6696 0.4896 0.48 re
f
173.1645 98.6696 95.9616 0.48 re
f
269.1261 98.6696 0.4896 0.48 re
f
269.6157 98.6696 118.728 0.48 re
f
388.3437 98.6696 0.4896 0.48 re
f
388.8333 98.6696 54.5904 0.48 re
f
443.4237 98.6696 0.4896 0.48 re
f
443.9133 98.6696 59.2416 0.48 re
f
503.1549 98.6696 0.4896 0.48 re
f
503.6445 98.6696 54.5904 0.48 re
f
103.8861 65.5496 0.4896 33.12 re
f
172.6749 65.5496 0.4896 33.12 re
f
269.1261 65.5496 0.4896 33.12 re
f
388.3437 65.5496 0.4896 33.12 re
f
443.4237 65.5496 0.4896 33.12 re
f
503.1549 65.5496 0.4896 33.12 re
f
Q
Q
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9 0 0 9 427.6092 446.339 Tm
0 0 0 1 k
(n)Tj
ET
/GS2 gs
0 0 0 0 k
391.5 432 9 10.098 re
f
177 259.723 87 15.699 re
f
/GS1 gs
BT
/F8 1 Tf
9 0 0 9 178 268.267 Tm
0 0 0 1 k
(Hydrochlorothiazide)Tj
ET
Q
endstream
endobj
33 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|]J/ӻ/_q_/pZim>VR+.c,| FTqλl(ezwx378j}Xs\{vSj]3Sx-GX!NI?/XaKteiIK1=xbMǠ&E4xeyïMvAK
7u
endstream
endobj
34 0 obj
<<
/LastChar 208
/FirstChar 32
/FontDescriptor 64 0 R
/Widths [229 0 0 0 0 794 0 0 320 323
0 628 239 365 239 392 529 529 529 529
529 529 529 529 529 529 0 0 0 0
610 0 0 690 642 683 744 598 554 736
767 362 0 0 0 940 733 750 598 0
635 519 657 763 678 964 0 604 0 0
0 0 0 0 0 557 536 423 570 443
298 448 552 317 280 496 306 840 565 502
554 534 404 377 344 584 466 0 501 463
447 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 607]
/Encoding 65 0 R
/Subtype /Type1
/BaseFont /VXJSEK+WarnockPro-SemiboldIt+XOGTYD
/Name /F10
/Type /Font
>>
endobj
35 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 66 0 R
>>
endobj
36 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
37 0 obj
<<
/Length 14323
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 39.024 29.4312 Tm
0 0 0 1 k
0.025 Tw
[(V)111(olume 34, Supplement No. 1 \320 Mar)37(ch 2007)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 540.0208 29.4312 Tm
0 0 0 1 k
(S87)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 717.0228 Tm
0 0 0 1 k
-0.018 Tw
(to 10,700, average roughly 4,500\) and long follow-up times \(3 to)Tj
0 -1.15789 TD
0.137 Tw
[(12 years, average roughly 6 years\). )18(These numbers have been)]TJ
T*
0.006 Tw
(necessary because of the low projected incident rate of dementia)Tj
0 -1.1579 TD
0.134 Tw
((range 1 to 5% per year) in the study populations. In turn the)Tj
0 -1.15789 TD
0.009 Tc
0.366 Tw
(costs have been formidable, not likely sustainable in the)Tj
T*
0 Tc
0.064 Tw
[(Canadian funding environment. )18(The two lar)17(gest trials \(WHIMS)]TJ
0 -1.1579 TD
0.284 Tw
[(and PREADVISE\) have tar)18(geted entirely non-selected study)]TJ
0 -1.15789 TD
0.163 Tw
(populations whereas the other trials have enriched their study)Tj
T*
0.123 Tw
[(samples with a limited number of )55(AD/dementia risk factors to)]TJ
0 -1.1579 TD
0.136 Tw
(increase the incidence rate and reduce the number of required)Tj
0 -1.15789 TD
0.023 Tw
[(participants. )18(These enriching risk factors have included a family)]TJ
T*
0.199 Tw
[(history of )55(AD/dementia in a first-degree relative,)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 236.7918 599.1578 Tm
0 0 0 1 k
(2)Tj
0.5 -0.00001 TD
(9)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 247.3271 596.0228 Tm
0 0 0 1 k
0.199 Tw
(old age,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 279.2899 599.1578 Tm
0 0 0 1 k
(3)Tj
0.5 -0.00001 TD
(0)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 585.0228 Tm
0 0 0 1 k
0.042 Tw
(systolic hypertension)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 120.8918 588.1578 Tm
0 0 0 1 k
(27,28)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 137.7752 585.0228 Tm
0 0 0 1 k
0.042 Tw
(and memory complaints.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 232.7603 588.1578 Tm
0 0 0 1 k
(31)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 241.8061 585.0228 Tm
0 0 0 1 k
0.042 Tw
[(Ef)17(forts will)]TJ
-21.24022 -1.15789 TD
0.303 Tw
(be warranted in future trial designs to increase the rate of)Tj
T*
0.295 Tw
(dementia progression by further enrichment techniques, that)Tj
0 -1.1579 TD
0.013 Tc
0.362 Tw
[(might include a lar)18(ger number of risk factors related to)]TJ
0 -1.15789 TD
0.02 Tc
0.684 Tw
(demographics, genomic profiles, vascular history and)Tj
T*
0 Tc
0.042 Tw
[(neuroimaging. )18(The settings of the research study and the source)]TJ
0 -1.1579 TD
0.102 Tw
[(of recruited subjects likely impact progression to )55(AD/dementia)]TJ
0 -1.15789 TD
0.265 Tw
(rates and should also be carefully considered as a potential)Tj
T*
0.025 Tw
(enrichment technique.)Tj
1.26316 -1.1579 TD
0.088 Tw
(Enrichment of study samples with )Tj
14.29985 0 TD
(AD/dementia risk factors)Tj
-15.56301 -1.1579 TD
0.166 Tw
(can be viewed as a potential strategy to optimally investigate)Tj
T*
0.341 Tw
(putative preventive agents. Smaller samples could establish)Tj
0 -1.15789 TD
0.345 Tw
(proof-of-principle as a prelude to lar)Tj
16.28123 0 TD
0 Tw
(ger)Tj
1.25684 0 TD
0.345 Tw
(-scale studies. )Tj
6.53022 0 TD
0 Tw
(This)Tj
-24.06829 -1.15791 TD
0.089 Tw
[(would also allow a range of existing/emer)18(ging epidemiological)]TJ
0 -1.1579 TD
0.256 Tw
[(leads to be pursued within a reasonable time frame. )18(W)40(ithin)]TJ
0 -1.15789 TD
-0.005 Tw
[(enriched studies the magnitude of treatment ef)18(fect sizes could be)]TJ
0 -1.1579 TD
0 Tw
(assessed.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9.5 0 0 9.5 40.024 398.0228 Tm
0 0 0 1 k
0.015 Tc
0.36 Tw
[((2) Projected rates of progression to )37(AD/dementia:)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 270.502 398.0228 Tm
0 0 0 1 k
0.015 Tc
(The)Tj
-24.26084 -1.15789 TD
0.02 Tc
0.467 Tw
(projected progression rates appear likely to have been)Tj
0 -1.1579 TD
0 Tc
-0.011 Tw
(overestimated in the initial primary prevention RCT)Tj
20.69258 0 TD
0 Tw
(s. )Tj
0.86035 0 TD
-0.011 Tw
(This raises)Tj
-21.55293 -1.1579 TD
0.02 Tc
0.571 Tw
(important considerations for future studies with some)Tj
0 -1.15789 TD
0 Tc
0 Tw
(speculation. )Tj
5.23223 0 TD
0.196 Tw
(The participation in a prevention trial may carry)Tj
-5.23223 -1.1579 TD
0.298 Tw
[(with it a beneficial impact on subjects\325)-474(health that extends)]TJ
T*
0.346 Tw
(beyond the intervention that is being tested. Subjects may)Tj
0 -1.15789 TD
0.02 Tc
0.419 Tw
(become more motivated to engage in health promoting)Tj
0 -1.1579 TD
0 Tc
0.344 Tw
(behaviours including diet, exercise patterns and other risk-)Tj
T*
0.006 Tc
0.369 Tw
[(modification. )18(They benefit from receiving careful medical)]TJ
T*
0 Tc
0.348 Tw
(follow-up within the trial over long periods of time, with)Tj
0 -1.15789 TD
0.011 Tw
(appropriate identification and treatment of new health problems.)Tj
T*
0.003 Tw
(In interventions that are non-prescriptional, the non-protocol use)Tj
-0.0001 Tc
(of)'
1.11473 0 Td
0 Tc
0.032 Tw
[(the tar)18(get treatments cannot be precluded as these are usually)]TJ
-1.11473 -1.15789 TD
-0.001 Tw
(readily available and subjects may wish to \324hedge their bets\325. By)Tj
0 -1.1579 TD
-0.036 Tw
(their nature, prevention trials may attract highly health-conscious)Tj
0 -1.15789 TD
0.267 Tw
(subjects who are not representative of the populations from)Tj
T*
-0.028 Tw
(which the initial )Tj
6.60856 0.00001 TD
(AD/dementia incidence rates have been derived.)Tj
-6.60856 -1.15791 TD
0.297 Tw
[(T)70(aken together)40(, these factors may culminate in unattainable)]TJ
0 -1.15789 TD
-0.028 Tw
(projected rates of )Tj
7.04984 0.00001 TD
(AD/dementia progression, resulting in the need)Tj
-7.04984 -1.1579 TD
0.074 Tw
(for additional time and further resources to complete trials \(see)Tj
T*
0 Tw
[(T)70(able\).)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9.5 0 0 9.5 40.024 156.0228 Tm
0 0 0 1 k
0.237 Tw
((3) Recruitment and retention:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 171.4492 156.0228 Tm
0 0 0 1 k
0.237 Tw
(Innovative strategies will be)Tj
-13.83423 -1.15789 TD
0.177 Tw
(needed to recruit and retain subjects in prevention trials. )Tj
24.2912 0.00001 TD
0 Tw
(The)Tj
-24.2912 -1.15791 TD
0.324 Tw
(recruitment of elderly participants into long-term studies is)Tj
0 -1.15789 TD
0.017 Tw
(known to be problematic,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 137.603 126.1577 Tm
0 0 0 1 k
(36)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 146.4134 123.0228 Tm
0 0 0 1 k
0.017 Tw
(yet this is the group with the highest)Tj
-11.19888 -1.15789 TD
0.086 Tw
[(risk of progression to )55(AD/dementia. )55(As previously pointed out,)]TJ
0 -1.1579 TD
0.051 Tw
[(there may be a potential problem of over)20(-representation of very)]TJ
0 -1.15789 TD
-0.026 Tw
(successfully aging subjects. )Tj
11.23289 0.00001 TD
(This has already been reported in the)Tj
-11.23289 -1.1579 TD
0.241 Tw
(Syst-Eur trial where subjects\325)Tj
12.99582 0.00001 TD
(median MMSE score at study)Tj
-12.99582 -1.15791 TD
0.02 Tc
0.506 Tw
(entry was 29.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 103.0172 71.1578 Tm
0 0 0 1 k
0.02 Tc
(27)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 116.9089 68.0228 Tm
0 0 0 1 k
0.02 Tc
0.506 Tw
(Recruitment problems may be further)Tj
20.23696 68.31579 TD
0 Tc
0.01 Tw
(exacerbated by the requirement of an informant for participation)Tj
0 -1.15789 TD
0.025 Tw
(in the trial.)Tj
1.26316 -1.15789 TD
0.209 Tw
(Retention of subjects will also pose problems, given long)Tj
-1.26316 -1.1579 TD
-0.021 Tw
(follow-up periods, modest perceived benefit and the potential for)Tj
0 -1.15789 TD
0.004 Tc
0.371 Tw
(the risk-benefit ratio to change during these periods \(e.g.)Tj
T*
0 Tc
0.053 Tw
[(NSAIDs in )55(ADAPT)74(, and estrogens in PREP)91(ARE and )18(WHIMS\).)]TJ
0 -1.1579 TD
0.003 Tw
(The first generation of trials underscores that non-adherence and)Tj
0 -1.15789 TD
0.228 Tw
(loss to follow-up will be significantly higher than predicted.)Tj
T*
0.097 Tw
(Provisions will have to be made for sample sizes that preserve)Tj
0 -1.1579 TD
0.083 Tw
[(adequate power through trials. )18(T)70(o enhance compliance, follow-)]TJ
0 -1.15789 TD
0.144 Tw
(up strategies that do not involve on-site visits \(e.g., telephone)Tj
T*
0.171 Tw
(interviews\) may be useful, as might the conduct of the study)Tj
0 -1.1579 TD
0.025 Tw
[(within usual care settings, i.e. General Practitioner of)18(fices.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9.5 0 0 9.5 309.16 574.0228 Tm
0 0 0 1 k
0.014 Tc
0.361 Tw
((4) Study endpoints:)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 403.5649 574.0228 Tm
0 0 0 1 k
0.014 Tc
0.361 Tw
(The clinically defined endpoints of)Tj
-9.93736 -1.15789 TD
0 Tc
0.198 Tw
[(AD/dementia prevention RCT)70(s have intrinsic limitations. )17(The)]TJ
0 -1.1579 TD
0.246 Tw
(validity of clinical states (normal, MCI, dementia) and state)Tj
0 -1.15789 TD
0.058 Tw
(transitions is limited by the absence of conclusively established)Tj
T*
-0.029 Tw
[(biological markers within a continuous disease process. )37(Y)100(et, time)]TJ
0 -1.1579 TD
0.03 Tw
[(to diagnosis of )55(AD/dementia is the primary outcome measure in)]TJ
0 -1.15789 TD
0 Tw
(RCT)Tj
1.875 0.00001 TD
-0.0001 Tc
(s)Tj
0.75113 0 Td
0 Tc
0.112 Tw
(and its accurate determination is critical. In multi-centre)Tj
-2.62613 -1.1579 TD
0.195 Tw
[(RCT)70(s, rater and centre biases in the measurement of time to)]TJ
T*
0.26 Tw
(diagnosis can be anticipated. On the horizon, biomarkers in)Tj
T*
0.02 Tc
0 Tw
(development)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 360.3176 478.1578 Tm
0 0 0 1 k
0.0199 Tc
(3)Tj
0.51994 -0.00001 TD
0.02 Tc
(7-39)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 382.8031 475.0228 Tm
0 0 0 1 k
0.02 Tc
0.491 Tw
(may assist, or even become surrogate)Tj
-7.7519 -1.1579 TD
0 Tc
0.107 Tw
(outcomes; however at present they cannot provide evidence of)Tj
0 -1.15789 TD
0 Tw
(ef)Tj
0.75879 0 TD
0.025 Tw
(ficacy independent of clinical criteria. )Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F8 1 Tf
9.5 0 0 9.5 309.16 442.0228 Tm
0 0 0 1 k
0.293 Tw
[((5) T)37(iming of interventions: )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 431.2913 442.0228 Tm
0 0 0 1 k
0.293 Tw
[(Prevention RCT)70(s will have to)]TJ
-12.85593 -1.1579 TD
0.02 Tc
0.5 Tw
(systematically investigate the relation between time of)Tj
0 -1.15789 TD
0 Tc
0.11 Tw
[(intervention and treatment ef)18(fect. )17(The )18(WHIMS trial found that)]TJ
0 -1.1579 TD
0.332 Tw
(treatment with estrogen plus progestin was unsuccessful in)Tj
T*
0.018 Tw
[(reducing the incidence of )55(AD/dementia in women aged 65 years)]TJ
0 -1.15789 TD
0.137 Tw
(or older)Tj
3.23467 0 TD
(,)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 342.2644 390.1578 Tm
0 0 0 1 k
(25)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 352.2135 387.0228 Tm
0 0 0 1 k
0.137 Tw
(though it has been suggested that if such treatment)Tj
-4.53195 -1.1579 TD
0.055 Tw
(were initiated around menopause (10 years earlier), there might)Tj
T*
0.009 Tc
0.366 Tw
[(have been a positive treatment ef)18(fect.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 471.5969 368.1578 Tm
0 0 0 1 k
0.009 Tc
(40)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 483.7512 365.0228 Tm
0 0 0 1 k
0.009 Tc
0.366 Tw
(There have been)Tj
-18.37802 -1.15789 TD
0 Tc
0.152 Tw
(suggestions that also other pharmacological interventions may)Tj
0 -1.1579 TD
-0.015 Tw
[(exert their most significant ef)18(fects in midlife, long before the age)]TJ
T*
0.025 Tw
[(of concern for )55(AD/dementia.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 419.0692 335.1578 Tm
0 0 0 1 k
(41)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 309.16 310.0228 Tm
0 0 0 1 k
(C)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 316.0183 310.0228 Tm
0 0 0 1 k
0.001 Tc
(ONCLUSIONS)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 321.16 295.0228 Tm
0 0 0 1 k
0.02 Tc
0.658 Tw
[(Research on the therapeutics of )55(AD/dementia has)]TJ
-1.26316 -1.15789 TD
0 Tc
0.24 Tw
(traditionally focused on treating diagnosed disease. However)Tj
0 -1.1579 TD
0.017 Tc
0.358 Tw
(researchers in the field have increasingly advocated that)Tj
0 -1.15789 TD
0 Tc
0.015 Tw
(attention be turned to the possibility of preventing dementia.)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
6.27 0 0 6.27 540.0693 265.1578 Tm
0 0 0 1 k
(42-44)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 309.16 251.0228 Tm
0 0 0 1 k
0.261 Tw
[(Currently the primary prevention of )55(AD/dementia should be)]TJ
0 -1.15789 TD
0.039 Tw
(understood as delaying the onset of diagnosable disease. In turn)Tj
T*
0.13 Tw
(this delay will ef)Tj
7.0644 0.00001 TD
[(fectively eliminate a number of )55(AD/dementia)]TJ
-7.0644 -1.15791 TD
0.169 Tw
(cases as individuals die of other causes before they cross the)Tj
0 -1.15789 TD
0.051 Tw
(threshold of diagnosable disease. Evidence of protective factors)Tj
T*
-0.011 Tw
[(already exists and of)18(fers good leads as to candidate interventions)]TJ
0 -1.1579 TD
0.181 Tw
[(that might be ef)18(fective. )17(The first prevention RCT)70(s have been)]TJ
0 -1.15789 TD
0.218 Tw
[(designed to test NSAIDs, hormonal therapy)65(, antihypertensive)]TJ
T*
0.184 Tw
(drugs, antioxidants and supplements. )Tj
15.77152 0.00001 TD
(The experience of these)Tj
-15.77152 -1.15791 TD
0.006 Tw
[(RCT)70(s has indicated safety concerns as a key issue in research on)]TJ
0 -1.15789 TD
0.048 Tw
(preventive interventions. Significant design and methodological)Tj
T*
0.049 Tw
(challenges have been highlighted that will need to be addressed)Tj
0 -1.1579 TD
0.025 Tw
(in future trials. )Tj
1.26316 -1.15789 TD
0.074 Tw
(It is foreseeable that regulatory authorities will be presented)Tj
-1.26316 -1.15789 TD
0.121 Tw
(with primary prevention RCT)Tj
12.20737 0.00001 TD
-0.0001 Tc
(s)Tj
0.76004 0 Td
0 Tc
(for approval and labelling. )Tj
11.32378 0.00001 TD
0 Tw
(The)Tj
-24.2912 -1.15791 TD
0.222 Tw
(regulatory criteria to evaluate such evidence will need to be)Tj
0 -1.15789 TD
0.307 Tw
[(developed. )18(These decisions about approval and labelling of)]TJ
ET
Q
endstream
endobj
38 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|]J/ӻ/_q_/pZim>VR+.c,| FTqλl(ezwx378j}Xs\{vSj]3Sx-GX!NI?/XaKteiIK1=xbMǠ&E4xeyïMvAK
7u
endstream
endobj
39 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 67 0 R
>>
endobj
40 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
41 0 obj
<<
/Length 15330
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
39.696 726 516 30 re
f
Q
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 39.696 749.8455 Tm
0 0 0 1 k
-0.0001 Tc
(THE)Tj
2.21865 0 Td
0 Tc
0.025 Tw
[(CANADIAN JOURNAL)-238(OF NEUROLOGICAL)-238(SCIENCES)]TJ
-2.21865 -80.04603 TD
0 Tw
(S88)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 40.024 717.024 Tm
0 0 0 1 k
0.045 Tw
(preventive interventions will have to define the acceptable risks)Tj
0 -1.1579 TD
0.025 Tw
[(and the standards for minimum treatment ef)18(fect sizes.)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 684.024 Tm
0 0 0 1 k
(D)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 46.8823 684.024 Tm
0 0 0 1 k
0.0011 Tc
(E)Tj
0.66714 -0.00001 TD
0.001 Tc
[(CLARA)75(T)-1(I)-1(O)-1(N)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9.5 0 0 9.5 52.024 669.024 Tm
0 0 0 1 k
0.02 Tc
0.405 Tw
(Howard Feldman receives support through the CIHR)Tj
-1.26316 -1.15789 TD
0 Tc
-0.025 Tw
[(operating grant IAP-73376 \322Preventing )55(AD and other dementias:)]TJ
0 -1.1579 TD
0.301 Tw
(The development of a statistical framework for randomised)Tj
0 -1.15789 TD
0.138 Tw
(controlled trials\323. Claudia Jacova is funded by a post-doctoral)Tj
T*
0.02 Tc
0.606 Tw
(Canadian Institutes of Health Research/Michael Smith)Tj
0 -1.1579 TD
0.441 Tw
[(Foundation for Health Research )18(T)35(raining Fellowship in)]TJ
0 -1.15789 TD
0 Tc
0.025 Tw
[(Neurobiology and Behaviour)55(. )]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
9.5 0 0 9.5 40.024 581.024 Tm
0 0 0 1 k
(R)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F1 1 Tf
7.125 0 0 7.125 46.8823 581.024 Tm
0 0 0 1 k
0.001 Tc
(EFERENCES)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 40.024 568.024 Tm
0 0 0 1 k
0.198 Tw
[(1.)-1015(Canadian Study of Health and )55(Aging )18(W)80(orking Group. Canadian)]TJ
2.82353 -1.05882 TD
0.165 Tw
[(Study of Health and )55(Aging: Study methods and prevalence of)]TJ
T*
0.025 Tw
(dementia. CMAJ. 1994; 150: 899-913.)Tj
-2.82353 -1.05882 TD
0.158 Tw
[(2.)-1015(Ostbye )18(T)74(, Crosse E. Net economic costs of dementia in Canada.)]TJ
2.82353 -1.05882 TD
0.025 Tw
(CMAJ. 1994; 151(10): 1457-64.)Tj
-2.82353 -1.05883 TD
0.039 Tw
[(3.)-1015(Sano M. Noncholiner)18(gic treatment options for )55(Alzheimer's disease.)]TJ
2.82353 -1.05882 TD
-0.0001 Tc
(J)Tj
0.66382 0 Td
0 Tc
0.025 Tw
[(Clin Psychiatry)65(. 2003; 64 Suppl 9: S23-8.)]TJ
-3.48734 -1.05882 TD
0.159 Tw
[(4.)-1015(Petersen RC. )55(Aging, mild cognitive impairment, and )55(Alzheimer's)]TJ
2.82353 -1.05882 TD
0.025 Tw
(disease. Neurol Clin. 2000; 18: 789-806.)Tj
-2.82353 -1.05882 TD
0.175 Tw
[(5.)-1015(Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S,)]TJ
2.82353 -1.05882 TD
-0.01 Tw
[(T)35(uokko H, et al. Prevalence and severity of cognitive impairment)]TJ
T*
0.266 Tw
(with and without dementia in an elderly population. Lancet.)Tj
T*
0.025 Tw
(1997; 349: 1793-6.)Tj
-2.82353 -1.05882 TD
0 Tw
(6.)Tj
1.76471 0 TD
-0.013 Tw
(Jack CR, Petersen RC, Xu )Tj
10.70279 0 TD
(Y)Tj
0.59301 0 TD
-0.0001 Tc
(,)Tj
0.48709 0 Td
0 Tc
(O'Brien PC, Smith GE, Ivnik RJ, et al.)Tj
-10.72407 -1.05883 TD
0.12 Tw
(Rates of hippocampal atrophy correlate with change in clinical)Tj
0 -1.05882 TD
0.025 Tw
(status in aging and )Tj
7.76578 0.00001 TD
(AD. Neurology)Tj
6.18027 0 TD
(.)Tj
0.52493 0 Td
(2000; 55: 484-9.)Tj
-17.29451 -1.05883 TD
0 Tw
(7.)Tj
1.76471 0 TD
0.031 Tw
(Kaye JA, Swihart )Tj
7.40592 0 TD
(T)Tj
0.53686 0 TD
-0.0001 Tc
(,)Tj
0.53093 0 Td
0 Tc
(Howieson D, Dame )Tj
8.20219 0 TD
(A, Moore MM, Karnos )Tj
9.65913 0 TD
(T)Tj
0.53687 0 TD
(,)Tj
-25.81307 -1.05884 TD
0.236 Tw
(et al. )Tj
2.6466 0 TD
(V)Tj
0.59301 0 TD
(olume loss of the hippocampus and temporal lobe in)Tj
-3.23961 -1.05883 TD
-0.016 Tw
(healthy elderly persons destined to develop dementia. Neurology)Tj
25.81307 0 TD
(.)Tj
-25.81307 -1.05883 TD
0.025 Tw
(1997; 48: 1297-304.)Tj
-2.82353 -1.05882 TD
0 Tw
(8.)Tj
1.76471 0 TD
-0.0001 Tc
(De)Tj
1.43741 0 Td
0 Tc
0.022 Tw
(Santi S, de Leon MJ, Rusinek H, Convit )Tj
16.47762 0 TD
0 Tw
(A, )Tj
1.22569 0 TD
(T)Tj
0.54101 0 TD
0.022 Tw
(arshish CY)Tj
4.36388 0 TD
-0.0001 Tc
(,)Tj
0.52148 0 Td
0 Tc
0 Tw
(Roche)Tj
-23.50828 -1.05884 TD
-0.012 Tw
(A, et al. Hippocampal formation glucose metabolism and volume)Tj
0 -1.05882 TD
0.025 Tw
(losses in MCI and )Tj
7.54385 0 TD
(AD. Neurobiol )Tj
6.24312 0.00001 TD
(Aging. 2001; 22: 529-39.)Tj
-16.61049 -1.05883 TD
0 Tw
(9.)Tj
1.76471 0 TD
(Drzezga )Tj
3.80215 0 TD
0.277 Tw
(A, Lautenschlager N, Siebner H, Riemenschneider M,)Tj
-2.74333 -1.05883 TD
(W)Tj
0.90405 0 TD
0.312 Tw
(illoch F)Tj
3.31541 0 TD
-0.0001 Tc
(,)Tj
0.8118 0 Td
0 Tc
(Minoshima S, et al. Cerebral metabolic changes)Tj
-5.03126 -1.05883 TD
0.299 Tw
(accompanying conversion of mild cognitive impairment into)Tj
0 -1.05882 TD
-0.016 Tw
(Alzheimer's disease: a PET)Tj
11.09134 0 TD
(follow-up study)Tj
6.27845 0.00001 TD
-0.0001 Tc
(.)Tj
0.48339 0 Td
0 Tc
(Eur J Nucl Med Mol)Tj
-17.85317 -1.05883 TD
0.025 Tw
(Imaging. 2003; 30: 1)Tj
8.42608 0 TD
0 Tw
(104-13.)Tj
-11.24961 -1.05883 TD
(10.)Tj
1.76471 0 TD
(Markesbery )Tj
5.21918 0 TD
0.212 Tw
(WR. Neuropathological criteria for the diagnosis of)Tj
-4.16035 -1.05883 TD
-0.017 Tw
(Alzheimer's disease. Neurobiol )Tj
12.62317 0 TD
(Aging. 1998; 18 (suppl 4): S13-9.)Tj
-15.4467 -1.05883 TD
(1)Tj
0.46313 0 TD
(1.)Tj
1.30158 0.00001 TD
-0.016 Tw
(Petersen RC, Doody R, Kurz )Tj
11.72403 0 TD
[(A, Mohs RC, Morris JC, Rabins PV)129(, et)]TJ
-10.66521 -1.05884 TD
0.047 Tw
(al. Current concepts in mild cognitive impairment. )Tj
20.74105 0.00001 TD
(Arch Neurol.)Tj
-20.74105 -1.05883 TD
0.025 Tw
(2001; 58(12): 1985-92.)Tj
-2.82353 -1.05882 TD
0 Tw
(12.)Tj
1.76471 0.00001 TD
0.337 Tw
(Brookmeyer R, Gray S, Kawas C. Projections of )Tj
22.33331 0.00001 TD
0 Tw
(Alzheimer's)Tj
-21.27448 -1.05884 TD
0.24 Tw
(disease in the United States and the public health impact of)Tj
0 -1.05882 TD
0.025 Tw
[(delaying disease onset. )55(Am J Public Health. 1998; 88: 1337-42.)]TJ
-2.82353 -1.05882 TD
0.218 Tw
[(13.)-515(Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H,)]TJ
2.82353 -1.05882 TD
0.085 Tw
[(V)111(erreault R, et al. Use of lipid-lowering agents, indication bias,)]TJ
T*
0.068 Tw
(and the risk of dementia in community-dwelling elderly people.)Tj
T*
0.025 Tw
(Arch Neurol. 2002; 59(2): 223-7.)Tj
-2.82353 -1.05882 TD
0.095 Tw
[(14.)-515(Jick H, Zornber)18(g GL, Jick SS, Seshadri S, Drachman DA. Statins)]TJ
2.82353 -1.05882 TD
0.025 Tw
(and the risk of dementia. Lancet. 2000; 356: 1627-31.)Tj
-2.82353 -1.05882 TD
0.124 Tw
[(15.)-515(W)80(olozin B, Siegel G. Decreased prevalence of )55(Alzheimer disease)]TJ
2.82353 -1.05882 TD
0.02 Tc
0.485 Tw
[(associated with 3-Hydroxy-3-Methyglutaryl Coenzyme )55(A)]TJ
T*
0 Tc
0.025 Tw
[(reductase inhibitors. )55(Arch Neurol. 2000; 57: 1439-43.)]TJ
-2.82353 -1.05882 TD
0.02 Tc
0.411 Tw
[(1)20(6)20(.)-495(McGeer PL, Schulzer M, McGeer EG. )55(Arthritis and anti-)]TJ
2.82353 -1.05882 TD
0.586 Tw
(inflammatory agents as possible protective factors for)Tj
T*
0 Tc
0.374 Tw
(Alzheimer's disease: a review of 17 epidemiologic studies.)Tj
T*
0.025 Tw
[(Neurology)65(. 1996; 47: 425-32.)]TJ
-2.82353 -1.05882 TD
0.049 Tw
[(17.)-515(in t'V)111(eld )18(VB, Ruitenber)17(g )55(A, Hofman )55(A, Launer LJ, van Duijn CM,)]TJ
2.82353 -1.05882 TD
0.003 Tw
[(Stijnen )18(T)74(, et al. Nonsteroidal antiinflammatory drugs and the risk)]TJ
T*
0.025 Tw
[(of )55(Alzheimer's disease. N Engl J Med. 2001; 345(21): 1515-21.)]TJ
-2.82353 -1.05882 TD
0.108 Tw
[(18.)-515(Zandi PP)111(, )55(Anthony JC, Khachaturian )55(AS, Stone SV)129(, Gustafson D,)]TJ
2.82353 -1.05882 TD
0.058 Tw
[(T)70(schanz JT)74(, et al. Reduced risk of )55(Alzheimer disease in users of)]TJ
T*
0.051 Tw
[(antioxidant vitamin supplements: the Cache County Study)65(. )55(Arch)]TJ
T*
0.025 Tw
(Neurol. 2004; 61(1): 82-8.)Tj
28.83953 75.84501 TD
0.02 Tc
0.395 Tw
[(1)20(9)20(.)-495(Henderson )18(VW)92(, Paganini-Hill )55(A, Emanuel CK, Dunn ME,)]TJ
2.82353 -1.05882 TD
0 Tc
0.126 Tw
(Buckwalter JG. Estrogen replacement therapy in older women.)Tj
T*
0.025 Tw
(Arch Neurol. 1994; 51: 896-900.)Tj
-2.82353 -1.05882 TD
0.187 Tw
[(20.)-515(Kawas C, Resnick S, Morrison )55(A, Brookmeyer R, Corrada MZ,)]TJ
2.82353 -1.05882 TD
0.27 Tw
[(Bacal C, et al. )55(A)-465(prospective study of estrogen replacement)]TJ
-0.0001 Tc
(t)'
0.27792 -0.00001 TD
0 Tc
0.313 Tw
[(herapy and the risk of developing )55(Alzheimer's disease: the)]TJ
-0.27792 -1.05882 TD
0.181 Tw
[(Baltimore Longitudinal Study of )55(Aging. Neurology)65(. 1997; 48:)]TJ
T*
0 Tw
(1517-21.)Tj
-2.82353 -1.05882 TD
0.009 Tw
[(21.)-515(Bosma H, van Boxtel MP)111(, Ponds R)55(W)92(, Houx PJ, Burdorf )55(A, Jolles J.)]TJ
2.82353 -1.05882 TD
0.317 Tw
(Mental work demands protect against cognitive impairment:)Tj
T*
0.287 Tw
[(MAAS prospective cohort study)65(. Exp )55(Aging Res. 2003; 29: )]TJ
T*
0 Tw
(33-45.)Tj
-2.82353 -1.05882 TD
-0.02 Tw
[(22.)-515(V)111(er)18(ghese J, Lipton RB, Katz MJ, Hall CB, Derby CA, Kuslansky G,)]TJ
2.82353 -1.05882 TD
-0.0001 Tc
(e)Tj
0.4439 -0.00001 TD
(t)Tj
0.56252 0 Td
0 Tc
0.035 Tw
[(al. Leisure activities and the risk of dementia in the elderly)65(. N)]TJ
-1.00642 -1.05882 TD
0.025 Tw
(Engl J Med. 2003; 348(25): 2508-16.)Tj
-2.82353 -1.05882 TD
-0.008 Tw
[(23.)-515(W)40(ilson RS, Mendes De Leon CF)80(, Barnes LL, Schneider JA, Bienias)]TJ
2.82353 -1.05882 TD
0.262 Tw
(JL, Evans DA, et al. Participation in cognitively stimulating)Tj
T*
0.113 Tw
[(activities and risk of incident )55(Alzheimer disease. JAMA. 2002;)]TJ
T*
0.025 Tw
(287: 742-8.)Tj
-2.82353 -1.05882 TD
-0.011 Tw
[(24.)-515(Lindsay J, Laurin D, )18(V)111(erreault R, Hebert R, Helliwell B, Hill GB, et)]TJ
2.82353 -1.05882 TD
0.15 Tw
[(al. Risk factors for )55(Alzheimer's disease: a prospective analysis)]TJ
T*
0.04 Tw
[(from the Canadian Study of Health and )55(Aging. )55(Am J Epidemiol.)]TJ
T*
0.025 Tw
(2002; 156 (5): 445-53.)Tj
-2.82353 -1.05882 TD
-0.006 Tw
[(25.)-515(Shumaker SA, Legault C, )18(Thal L, )18(W)80(allace RB, Ockene JK, Hendrix)]TJ
2.82353 -1.05882 TD
0.052 Tw
(SL, et al. Estrogen plus progestin and the incidence of dementia)Tj
T*
0.149 Tw
(and mild cognitive impairment in postmenopausal women: the)Tj
T*
0.084 Tw
(women's health initiative memory study: randomized controlled)Tj
T*
0.025 Tw
(trial. JAMA. 2003; 289(20): 2651-62.)Tj
-2.82353 -1.05882 TD
0.054 Tw
[(26.)-515(Shumaker SA, Legault C, Kuller L, Rapp SR, )18(Thal L, Lane DS, et)]TJ
2.82353 -1.05882 TD
0.001 Tc
0.374 Tw
(al. Conjugated equine estrogens and incidence of probable)Tj
T*
0 Tc
0.345 Tw
(dementia and mild cognitive impairment in postmenopausal)Tj
T*
-0.005 Tw
[(women: )18(W)80(omen's Health Initiative Memory Study)65(. JAMA. 2004;)]TJ
T*
0.025 Tw
(291(24): 2947-58.)Tj
-2.82353 -1.05882 TD
0.336 Tw
[(27.)-515(Forette F)80(, Seux ML, Staessen JA, )18(Thijs L, Birkenhager )17(WH,)]TJ
2.82353 -1.05882 TD
0.169 Tw
(Babarskiene MR, et al. Prevention of dementia in randomised)Tj
T*
-0.014 Tw
(double-blind placebo-controlled Systolic Hypertension in Europe)Tj
T*
0.025 Tw
((Syst-Eur) trial. Lancet. 1998; 352: 1347-51.)Tj
-2.82353 -1.05882 TD
0.009 Tw
[(28.)-515(Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman )55(A, Olofsson B,)]TJ
2.82353 -1.05882 TD
0.328 Tw
[(et al. )18(The study on cognition and prognosis in the elderly)]TJ
T*
0.02 Tc
0.36 Tw
((SCOPE): principal results of a randomized double-blind)Tj
T*
0 Tc
0.025 Tw
(intervention trial. J Hypertens. 2003; 21: 875-86.)Tj
-2.82353 -1.05882 TD
0.292 Tw
[(29.)-515(Boyles S. Naproxen may increase risk of heart disease. 2005.)]TJ
2.82353 -1.05882 TD
0.025 Tw
[(A)74(vailable from: http://www)65(.medscape.com/viewarticle/496403.)]TJ
-2.82353 -1.05882 TD
0.166 Tw
[(30.)-515(CHS Coordinating Center)55(. Ginkgo Evaluation of Memory Study)65(.)]TJ
2.82353 -1.05882 TD
0.025 Tw
[(2003. )55(A)74(vailable from: http://www)65(.nccam-ginkgo.or)18(g.)]TJ
-2.82353 -1.05882 TD
0.017 Tw
[(31.)-515(V)111(ellas B, )55(Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H. )18(The)]TJ
2.82353 -1.05882 TD
0.201 Tw
[(GuidAge study: Methodological issues. )55(A)-396(5-year double-blind)]TJ
T*
0.021 Tw
[(randomized trial of the ef)18(ficacy of EGb 761(R) for prevention of)]TJ
T*
0.025 Tw
(Alzheimer disease in patients over 70 with a memory complaint.)Tj
T*
0 Tw
(Neurology)Tj
4.21142 0.00001 TD
(.)Tj
0.52491 0 Td
0.025 Tw
(2006 Nov 14;67(9 Suppl 3):S6-1)Tj
13.22877 0.00001 TD
(1. )Tj
-20.78863 -1.05884 TD
0 Tw
(32.)Tj
1.76471 0.00001 TD
0.018 Tc
0.357 Tw
(Kryscio RJ, Mendiondo MS, Schmitt F)Tj
18.03161 0.00001 TD
(A, Markesbery )Tj
7.1938 0.00001 TD
0 Tw
(WR.)Tj
-24.16659 -1.05884 TD
0 Tc
0.164 Tw
(Designing a lar)Tj
6.41866 0.00001 TD
(ge prevention trial: statistical issues. Stat Med.)Tj
-6.41866 -1.05883 TD
0.025 Tw
(2004; 23: 285-96.)Tj
-2.82353 -1.05882 TD
0 Tw
(33.)Tj
1.76471 0.00001 TD
0.366 Tw
(Sjogren M, Gustafsson K, Syversen S, Olsson )Tj
21.16882 0.00001 TD
(A, Edman )Tj
4.98114 0.00001 TD
0 Tw
(A,)Tj
-25.09114 -1.05884 TD
0.128 Tw
(Davidsson P)Tj
5.04422 0.00001 TD
-0.0001 Tc
(,)Tj
0.62756 0 Td
0 Tc
(et al. )Tj
2.43114 0.00001 TD
(T)Tj
0.57593 0.00001 TD
(reatment with simvastatin in patients with)Tj
-8.67885 -1.05884 TD
-0.011 Tw
(Alzheimer's disease lowers both alpha- and beta-cleaved amyloid)Tj
0 -1.05882 TD
-0.008 Tw
(precursor protein. Dement Geriatr Cogn Disord. 2003; 16: 25-30.)Tj
-2.82353 -1.05882 TD
0 Tw
(34.)Tj
1.76471 0.00001 TD
0.121 Tw
(Fassbender K, Simons M, Ber)Tj
12.51901 0.00001 TD
(gmann C, Stroick M, Lutjohann D,)Tj
-11.46019 -1.05884 TD
-0.003 Tw
(Keller P)Tj
3.19041 0.00001 TD
-0.0001 Tc
(,)Tj
0.4971 0 Td
0 Tc
(et al. Simvastatin strongly reduces levels of )Tj
17.58697 0.00001 TD
0 Tw
(Alzheimer's)Tj
-21.27448 -1.05884 TD
-0.036 Tw
(disease beta -amyloid peptides )Tj
12.29435 0.00001 TD
(Abeta 42 and )Tj
5.417 0.00001 TD
(Abeta 40 in vitro and)Tj
-17.71136 -1.05884 TD
0.025 Tw
(in vivo. Proc Natl )Tj
7.4047 0.00001 TD
(Acad Sci USA. 2001; 98: 5856-61.)Tj
-10.22823 -1.05883 TD
0 Tw
(35.)Tj
1.76471 0.00001 TD
0.169 Tw
(Mattson MP)Tj
5.02986 0.00001 TD
-0.0001 Tc
(,)Tj
0.66834 0 Td
0 Tc
(Haberman F)Tj
5.05887 0.00001 TD
-0.0001 Tc
(.)Tj
0.66835 0 Td
0 Tc
(Folate and homocysteine metabolism:)Tj
-10.3666 -1.05884 TD
0.008 Tc
0.367 Tw
(therapeutic tar)Tj
6.21265 0.00001 TD
(gets in cardiovascular and neurodegenerative)Tj
-6.21265 -1.05883 TD
0 Tc
0.025 Tw
(disorders. Curr Med Chem. 2003; 10: 1923-9.)Tj
-2.82353 -1.05882 TD
0 Tw
(36.)Tj
1.76471 0.00001 TD
0.074 Tw
(Helliwell B, )Tj
5.23046 0.00001 TD
(A)Tj
0.63012 0.00001 TD
(ylesworth R, McDowell I, Baumgarten M, Sykes E.)Tj
-4.80175 -1.05884 TD
0.12 Tw
(Correlates of nonparticipation in the Canadian Study of Health)Tj
0 -1.05882 TD
0 Tw
(and )Tj
1.66392 0.00001 TD
0.025 Tw
(Aging. Int Psychogeriatr)Tj
9.85297 0.00001 TD
(.)Tj
0.52494 0 Td
(2001; 13 Supp 1: 49-56.)Tj
-14.86537 -1.05884 TD
0 Tw
(37.)Tj
1.76471 0.00001 TD
0.002 Tw
(Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD,)Tj
1.05882 -1.05883 TD
0.233 Tw
(et al. Biological markers for therapeutic trials in )Tj
21.27447 0.00001 TD
0 Tw
(Alzheimer's)Tj
-21.27447 -1.05883 TD
0.153 Tw
(disease. Proceedings of the biological markers working group;)Tj
0 -1.05882 TD
0 Tw
(NIA)Tj
1.94024 0.00001 TD
-0.031 Tw
(initiative on neuroimaging in )Tj
11.70574 0.00001 TD
(Alzheimer's disease. Neurobiol)Tj
-13.64598 -1.05884 TD
0.025 Tw
(Aging. 2003; 24: 521-36.)Tj
ET
Q
endstream
endobj
42 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|m]̗ǯḯr8 UaJ+sA1>Dcw#O*T V8Ux]t62;njn9=q5ُ.)VHcU$dO%EO
2ҴӤϘnĎcPv"WצUK7q
endstream
endobj
43 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 68 0 R
>>
endobj
44 0 obj
<<
/Filter /FlateDecode
/Length 10
>>
stream
x+ |
endstream
endobj
45 0 obj
<<
/Length 2374
>>
stream
/GS0 gs
1 g
0 783 0 0 re
f
q
/GS1 gs
0 0 0 0 k
39.024 726 516 30 re
f
Q
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 308.5412 749.8455 Tm
0 0 0 1 k
0.025 Tw
[(LE JOURNAL)-238(CANADIEN DES SCIENCES NEUROLOGIQUES)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F2 1 Tf
9 0 0 9 39.024 29.4312 Tm
0 0 0 1 k
0.025 Tw
[(V)111(olume 34, Supplement No. 1 \320 Mar)37(ch 2007)]TJ
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
9 0 0 9 540.0208 29.4312 Tm
0 0 0 1 k
(S89)Tj
ET
Q
/GS2 gs
/GS1 gs
q
BT
/F0 1 Tf
8.5 0 0 8.5 40.024 717.7065 Tm
0 0 0 1 k
0.138 Tw
[(38.)-515(Hampel H, Mitchell )55(A, Blennow K, Frank RA, Brettschneider S,)]TJ
2.82353 -1.05882 TD
0.007 Tw
[(W)80(eller L, et al. Core biological marker candidates of )55(Alzheimer's)]TJ
T*
0.117 Tw
(disease - perspectives for diagnosis, prediction of outcome and)Tj
T*
0.234 Tw
[(reflection of biological activity)65(. J Neural )18(T)35(ransm. 2004; 1)36(1)37(1: )]TJ
T*
0 Tw
(247-72.)Tj
-2.82353 -1.05882 TD
(3)Tj
0.5 -0.00001 TD
-0.015 Tw
[(9.)-515(Klunk )18(WE, Engler H, Nordber)18(g )55(A, Bacskai BJ, )18(W)80(ang )36(Y)129(, Price JC, et)]TJ
2.32353 -1.05882 TD
0.349 Tw
[(al. Imaging the pathology of )55(Alzheimer's disease: amyloid-)]TJ
T*
0.027 Tw
[(imaging with positron emission tomography)65(. Neuroimaging Clin)]TJ
-0.0001 Tc
(N)'
0.94199 0 Td
0 Tc
0.025 Tw
(Am. 2003; 13: 781-9, ix.)Tj
-3.76552 -1.05882 TD
0.012 Tc
0.363 Tw
[(4)12(0)12(.)-503(Resnick SM, Henderson )18(VW)92(. Hormone therapy and risk of)]TJ
2.82353 -1.05882 TD
0 Tc
0.025 Tw
(Alzheimer disease: a critical time. JAMA. 2002; 288: 2170-2.)Tj
28.83953 10.58824 TD
0.128 Tw
[(41.)-515(Fratiglioni L, Paillard-Bor)18(g S, )18(W)40(inblad B. )55(An active and socially)]TJ
2.82353 -1.05882 TD
0.179 Tw
(integrated lifestyle in late life might protect against dementia.)Tj
T*
0.025 Tw
(Lancet Neurol. 2004; 3: 343-53.)Tj
-2.82353 -1.05882 TD
0.022 Tw
[(42.)-515(Sano M. Current concepts in the prevention of )55(Alzheimer's disease.)]TJ
2.82353 -1.05882 TD
0.025 Tw
[(CNS Spectr)55(. 2003; 8: 846-53.)]TJ
-2.82353 -1.05882 TD
(4)Tj
0.5 -0.00001 TD
0.196 Tw
[(3.)-515(Black SE, Patterson C, Feightner J. Preventing dementia. Can J)]TJ
2.32353 -1.05882 TD
0.025 Tw
(Neurol Sci. 2001; 28 Suppl 1: S56-66.)Tj
-2.82353 -1.05882 TD
0.06 Tw
[(44.)-515(Knopman D. Pharmacotherapy for )55(Alzheimer's disease: 2002. Clin)]TJ
2.82353 -1.05882 TD
0.025 Tw
(Neuropharmacol. 2003; 26: 93-101.)Tj
ET
Q
endstream
endobj
46 0 obj
<<
/Filter /FlateDecode
/Length 238
>>
stream
xmK0
BN,i$mZ:Ӫ[ׁEy{b|m]̗ǯḯr8 UaJ+sA1>Dcw#O*T V8Ux]t62;njn9=q5ُ.)VHcU$dO%EO
2ҴӤϘnĎcPv"WצUK7q
endstream
endobj
47 0 obj
<<
/Type /Annot
/Subtype /Link
/Rect [7.7999997 14.264648 133.62 22.189453]
/Border [0 0 0]
/A 69 0 R
>>
endobj
48 0 obj
<<
/FontFile3 70 0 R
/Ascent 912
/XHeight 921
/Type /FontDescriptor
/StemV 25
/CapHeight 676
/FontName /LLIVZZ+Times-Bold
/StemH 0
/Descent -203
/FontBBox [-168 -218 998 934]
/Flags 262178
/ItalicAngle 0
>>
endobj
49 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 40 /parenleft /parenright 45 /hyphen /period /slash 58
/colon 65 /A /B /C /D /E /F /G /H
/I 76 /L /M /N /O /P 82 /R /S
/T /U /V /W 89 /Y 97 /a /b /c
/d /e /f /g 105 /i 108 /l /m /n
/o /p 114 /r /s /t 118 /v 121 /y
131 /Eacute 142 /eacute 213 /quoteright]
/Type /Encoding
>>
endobj
50 0 obj
<<
/FontFile3 71 0 R
/Ascent 684
/XHeight 677
/Type /FontDescriptor
/StemV 23
/CapHeight 654
/FontName /XRAHFI+Times-Italic
/StemH 0
/Descent -205
/FontBBox [-169 -217 1009 884]
/Flags 98
/ItalicAngle -11
>>
endobj
51 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 44 /comma 46 /period /slash /zero /one /two
/three /four 55 /seven 58 /colon 65 /A 67 /C
/D 70 /F 72 /H 74 /J 77 /M /N
80 /P 82 /R /S 86 /V 97 /a 99
/c /d /e 103 /g /h /i 108 /l /m
/n /o /p /q /r /s /t /u /v /w
208 /endash]
/Type /Encoding
>>
endobj
52 0 obj
<<
/FontFile3 72 0 R
/Ascent 684
/XHeight 677
/Type /FontDescriptor
/StemV 84
/CapHeight 662
/FontName /CICWSW+Times-Roman
/StemH 0
/Descent -215
/FontBBox [-168 -218 1000 899]
/Flags 34
/ItalicAngle 0
>>
endobj
53 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 36 /dollar /percent 39 /quotesingle /parenleft /parenright 44
/comma /hyphen /period /slash /zero /one /two /three /four /five
/six /seven /eight /nine /colon /semicolon 61 /equal 65 /A
/B /C /D /E /F /G /H /I /J /K
/L /M /N /O /P /Q /R /S /T /U
/V /W /X /Y /Z 97 /a /b /c /d
/e /f /g /h /i /j /k /l /m /n
/o /p /q /r /s /t /u /v /w /x
/y /z 136 /agrave 141 /ccedilla /eacute /egrave /ecircumflex 148
/icircumflex 153 /ocircumflex 158 /ucircumflex 203 /Agrave 209 /emdash /quotedblleft
/quotedblright /quoteleft /quoteright]
/Type /Encoding
>>
endobj
54 0 obj
<<
/Type /Font
/Subtype /CIDFontType2
/BaseFont /AAALBE+NotoSans
/CIDSystemInfo 73 0 R
/FontDescriptor 74 0 R
/W [0 [600]
3 [260]
17 [268 372 572 572]
22 [572]
24 [572 572 572]
29 [268]
38 [632]
51 [605]
54 [549]
56 [731]
68 [561 615]
71 [615 564]
74 [615 618 258]
79 [258 935 618 605 615]
85 [413 479 361 618 508]
92 [510]
]
/CIDToGIDMap 75 0 R
>>
endobj
55 0 obj
<<
/Filter /FlateDecode
/Length 327
>>
stream
x]j0E
-EpP܀1/n?PBvs*3
Tn&vF;kH^FRwʹKV]D}iAd>8YnzГޝ&י|?W7k'3ɝsھ=ɀ}Rn!5[,!iMrv~2;2߽|{C]0S !qxT'@H|dJ{[D!{f5VQHDC&`
xg`X0TxLXUwE%sln-S=[X
endstream
endobj
56 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
57 0 obj
<<
/Name /Fm1
/BBox [-0.1594 -1.53971 2.26236 3.03065]
/Subtype /Form
/Resources <<
/XObject <<
/Im1 76 0 R
>>
/ProcSet [/PDF /ImageB]
/ExtGState <<
/GS3 58 0 R
>>
>>
/Type /XObject
/Length 35
/Matrix [1 0 0 1 0 0]
/OPI <<
/2.0 <<
/IncludedImageQuality 1
/Inks [/monochrome (Black) 1]
/Overprint false
/F (Production Archives:Production archive: Journal Old issues:33SUPPLEMENTS:DEMENTIA SUPPLEMENT:Figures:2946 figure.tif)
/CropRect [86.348 498.431 1950 1792.93506]
/Size [1950 2059]
/Version 2
/Type /OPI
>>
>>
/FormType 1
>>
stream
/GS3 gs
q
1 0 0 1 0 0 cm
/Im1 Do
Q
endstream
endobj
58 0 obj
<<
/SM 0.01
/FL 1
/Type /ExtGState
>>
endobj
59 0 obj
<<
/FontFile3 77 0 R
/Ascent 717
/XHeight 737
/Type /FontDescriptor
/StemV 88
/CapHeight 687
/FontName /QRNEIP+Helvetica
/StemH 0
/Descent -194
/FontBBox [-166 -224 1000 931]
/Flags 32
/ItalicAngle 0
>>
endobj
60 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 45 /hyphen /period 48 /zero 50 /two /three
/four 54 /six 56 /eight /nine /colon 65 /A 67
/C 74 /J 77 /M /N 80 /P 82 /R
/S 97 /a /b /c /d /e /f /g /h
/i 108 /l /m /n /o /p 114 /r /s
/t /u 119 /w 121 /y /z 213 /quoteright]
/Type /Encoding
>>
endobj
61 0 obj
<<
/FontFile3 78 0 R
/Ascent 700
/XHeight 685
/Type /FontDescriptor
/StemV 79
/CapHeight 669
/FontName /FLDMAH+Times-BoldItalic
/StemH 0
/Descent -204
/FontBBox [-200 -216 992 921]
/Flags 262242
/ItalicAngle -11
>>
endobj
62 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 40 /parenleft /parenright 47 /slash 49 /one /two
/three /four /five 58 /colon 65 /A 68 /D 70
/F 72 /H 80 /P 82 /R /S /T 97
/a 99 /c /d /e /f /g /h /i /j
108 /l /m /n /o /p 114 /r /s /t
/u /v 121 /y /z]
/Type /Encoding
>>
endobj
63 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
64 0 obj
<<
/FontFile3 79 0 R
/Ascent 699
/XHeight 724
/Type /FontDescriptor
/StemV 117
/CapHeight 658
/FontName /VXJSEK+WarnockPro-SemiboldIt+XOGTYD
/StemH 0
/Descent -214
/FontBBox [-218 -579 1573 1006]
/Flags 34
/ItalicAngle 0
>>
endobj
65 0 obj
<<
/BaseEncoding /MacRomanEncoding
/Differences [32 /space 37 /percent 40 /parenleft /parenright 43 /plus /comma
/hyphen /period /slash /zero /one /two /three /four /five /six
/seven /eight /nine 62 /greater 65 /A /B /C /D
/E /F /G /H /I 77 /M /N /O /P
82 /R /S /T /U /V /W 89 /Y 97
/a /b /c /d /e /f /g /h /i /j
/k /l /m /n /o /p /q /r /s /t
/u /v 120 /x /y /z 208 /endash]
/Type /Encoding
>>
endobj
66 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
67 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
68 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
69 0 obj
<<
/S /URI
/URI (https://doi.org/10.1017/S0317167100005631)
>>
endobj
70 0 obj
<<
/Subtype /Type1C
/Length 5099
/Length1 5099
>>
stream
LLIVZZ+Times-Bold @